

## REVIEW

10.1111/j.1469-0691.2008.02070.x

## Then and now: use of 16S rDNA gene sequencing for bacterial identification and discovery of novel bacteria in clinical microbiology laboratories

P. C. Y. Woo<sup>1,2,3\*</sup>, S. K. P. Lau<sup>1,2,3\*</sup>, J. L. L. Teng<sup>3</sup>, H. Tse<sup>1,2,3</sup> and K.-Y. Yuen<sup>1,2,3</sup>

<sup>1</sup>State Key Laboratory of Emerging Infectious Diseases, <sup>2</sup>Research Centre of Infection and Immunology and <sup>3</sup>Department of Microbiology, The University of Hong Kong, Hong Kong, China

### ABSTRACT

In the last decade, as a result of the widespread use of PCR and DNA sequencing, 16S rDNA sequencing has played a pivotal role in the accurate identification of bacterial isolates and the discovery of novel bacteria in clinical microbiology laboratories. For bacterial identification, 16S rDNA sequencing is particularly important in the case of bacteria with unusual phenotypic profiles, rare bacteria, slow-growing bacteria, uncultivable bacteria and culture-negative infections. Not only has it provided insights into aetiologies of infectious disease, but it also helps clinicians in choosing antibiotics and in determining the duration of treatment and infection control procedures. With the use of 16S rDNA sequencing, 215 novel bacterial species, 29 of which belong to novel genera, have been discovered from human specimens in the past 7 years of the 21st century (2001–2007). One hundred of the 215 novel species, 15 belonging to novel genera, have been found in four or more subjects. The largest number of novel species discovered were of the genera *Mycobacterium* ( $n = 12$ ) and *Nocardia* ( $n = 6$ ). The oral cavity/dental-related specimens ( $n = 19$ ) and the gastrointestinal tract ( $n = 26$ ) were the most important sites for discovery and/or reservoirs of novel species. Among the 100 novel species, *Streptococcus sinensis*, *Laribacter hongkongensis*, *Clostridium hathewayi* and *Borrelia spielmanii* have been most thoroughly characterized, with the reservoirs and routes of transmission documented, and *S. sinensis*, *L. hongkongensis* and *C. hathewayi* have been found globally. One of the greatest hurdles in putting 16S rDNA sequencing into routine use in clinical microbiology laboratories is automation of the technology. The only step that can be automated at the moment is input of the 16S rDNA sequence of the bacterial isolate for identification into one of the software packages that will generate the result of the identity of the isolate on the basis of its sequence database. However, studies on the accuracy of the software packages have given highly varied results, and interpretation of results remains difficult for most technicians, and even for clinical microbiologists. To fully utilize 16S rDNA sequencing in clinical microbiology, better guidelines are needed for interpretation of the identification results, and additional/supplementary methods are necessary for bacterial species that cannot be identified confidently by 16S rDNA sequencing alone.

**Keywords** 16S rDNA gene, bacteria, discovery, identification, review, sequencing

**Accepted:** 11 June 2008

*Clin Microbiol Infect* 2008; **14**: 908–934

### INTRODUCTION

One and a half centuries after the 22-year-old Charles Darwin's 5-year voyage on HMS *Beagle*, the analysis of small rDNA gene sequences is another important landmark in the study of the evolution and classification of living organisms. Traditionally, living organisms were classified, according to similarities and differences in their phenotypic characteristics, into prokaryotes and

Corresponding author and reprint requests: K. Y. Yuen, State Key Laboratory of Emerging Infectious Diseases, Department of Microbiology, The University of Hong Kong, University Pathology Building, Queen Mary Hospital, Hong Kong, China  
E-mail: [hkumicro@hkucc.hku.hk](mailto:hkumicro@hkucc.hku.hk)

\*P. C. Y. Woo and S. K. P. Lau contributed equally to the article.

eukaryotes, and these were in turn further classified into various kingdoms, phyla, classes, orders, families, genera and species. However, objective taxonomic classification by these methods can be difficult because of variations in phenotypic characteristics. Three decades ago, Carl Woese and others started to analyse and sequence the 16S rDNA genes of various bacteria, using DNA sequencing, a state-of-the-art technology at that time, and used the sequences for phylogenetic studies [1,2]. The invention of PCR and automated DNA sequencing two decades ago, and subsequent work on 16S rDNA sequencing of bacteria, as well as 18S rDNA sequencing of eukaryotes, has led to the accumulation of a vast amount of sequence data on the rDNA genes of the smaller subunit of the ribosomes in a large number of living organisms. Comparison of these sequences has shown that the rDNA gene sequences are highly conserved within living organisms of the same genus and species, but that they differ between organisms of other genera and species. Using these rDNA gene sequences for phylogenetic studies, three domains of life, Archaea, Bacteria and Eukarya, as opposed to the traditional classification of living organisms into prokaryotes and eukaryotes only, were described [3].

Among the three domains of life, the largest amount of rDNA gene sequencing work concerns bacteria. Using 16S rDNA sequences, numerous bacterial genera and species have been reclassified and renamed, classification of uncultivable bacteria has been made possible, phylogenetic relationships have been determined, and the discovery and classification of novel bacterial species has been facilitated. In the last decade, sequencing of various bacterial genomes and comparison between genome and 16S rDNA gene phylogeny has confirmed the representativeness of the 16S rDNA gene in bacterial phylogeny [4].

As a result of the increasing availability of PCR and DNA sequencing facilities, the use of 16S rDNA sequencing has not been limited to research purposes, but has also been exploited in clinical microbiology laboratories. Accurate identification of bacterial isolates is one of the most important functions of clinical microbiology laboratories. On a patient-to-patient basis, accurate identification is crucial in determining whether the isolate is causing genuine infection or is simply a colonizer or contaminant, the choice

and duration of antibiotic treatment, and the appropriate infection control procedures. On a population scale, accurate identification is important in analysing the epidemiology, antibiotic resistance patterns, treatment plans and outcomes of infections associated with a particular bacterium. Traditionally, identification of bacteria in clinical microbiology laboratories was performed using phenotypic tests, including Gram smear and biochemical tests, taking into account culture requirements and growth characteristics. However, these methods of bacterial identification have major limitations. First, organisms with biochemical characteristics that do not fit into the patterns of any known genus and species are occasionally encountered. Second, they cannot be used for uncultivable organisms. Third, identification of some particular groups of bacteria, such as anaerobes and mycobacteria, would require additional equipment and expertise, which are not available in most clinical microbiology laboratories. Using 16S rDNA sequencing, these problems can be overcome by a single technology, which also facilitates the discovery of novel genera and species.

In this article, the use of 16S rDNA sequencing in clinical microbiology laboratories for bacterial identification, the discovery of novel bacterial genera and species, the detection of uncultivable bacteria and the diagnosis of culture-negative infections are reviewed. Automation of 16S rDNA sequencing and the usefulness and limitations of 16S rDNA sequencing in clinical microbiology laboratories are also discussed. The technological aspects of 16S rDNA sequencing are not included in this review.

## METHODS

In the section on 'Novel bacterial genus and species discovery', novel species discovered from human specimens that were reported during the first 7 years of the 21st century (2001–2007) in the English literature are reviewed. For initial screening, 'gen. nov.' and 'sp. nov.' were used as the key words for a Medline search. The results were manually screened for novel bacterial species isolated from human specimens, regardless of the criteria used for their definition. Bacteria that were discovered only in non-human specimens were excluded. Bacteria that were discovered, characterized and named before 2001, but were renamed after 2001 (e.g. *Streptococcus lutetiensis* and *S. pasteurianus* [5]), and those that were further subclassified (e.g. *S. pseudopneumoniae* [6]) because of acquisition of new information such as 16S rDNA sequences or phenotypic test results, were also not included.

Additional reports on infections associated with each of the novel species isolated from human specimens, as well as those concerning their isolation from non-human specimens, were searched. All novel species that have been found in four or more subjects are presented.

## USE OF 16S rDNA SEQUENCING IN CLINICAL MICROBIOLOGY LABORATORIES

### Bacterial identification

Rapid and accurate identification of bacterial isolates is a fundamental task in clinical microbiology, and provides insights into aetiologies of infectious disease and appropriate antibiotic treatment. Although conventional phenotypic methods are relatively inexpensive and allow identification of most commonly encountered bacteria, certain groups of bacteria are difficult to identify, and special equipment and expertise may be required, e.g. gas chromatography–mass spectrometry for anaerobes. These methods also fail in cases of rare bacteria or bacteria with ambiguous profiles. Moreover, phenotypic methods rely on the availability of pure culture and are dependent on subsequent growth characteristics and biochemical profiling. Therefore, considerable time is required for slow-growing bacteria to be identified. 16S rDNA sequencing represents a universal technology that, theoretically, provides solutions to these problems, yielding unambiguous data, even for unusual and slow-growing isolates, often within 48 h, which are reproducible among laboratories.

*Identification of rare bacteria and bacteria with unusual phenotypic profiles.* 16S rDNA sequencing is particularly useful in identifying unusual bacteria that are difficult to identify by conventional methods, providing genus identification in >90% of cases, and identification of 65–83% of these at the species level [7,8]. The MicroSeq 500 16S rDNA-based identification system was also able to identify 81% of clinically significant bacterial isolates with ambiguous biochemical profiles and 89.2% of unusual aerobic Gram-negative bacilli to the species level [9,10].

In many situations, 16S rDNA sequencing is the ultimate solution to identification of aetiological agents of infectious diseases caused by rarely encountered bacteria [11–22]. This not only allows correct identification and selection of appropriate

treatment, but also contributes to a better understanding of the epidemiology and pathogenic role of these bacteria, which has not been possible in the past. For example, using 16S rDNA sequencing, cases of invasive *Streptococcus iniae* infections, which had previously been reported only in North America, have been recognized in Asia [23–27].

Unlike phenotypic identification, which can be affected by the presence or absence of non-housekeeping genes or by variability in expression of characters, 16S rDNA sequencing provides accurate identification of isolates with atypical phenotypic characteristics. Using the technique, it has been possible to identify thermotolerant *Campylobacter fetus* strains as important causes of bacteraemia in immunocompromised patients [28]. Similar applications have also been shown to have significant impacts on the decision of whether to prescribe antibiotic treatment [29–31] and on the choice of specific antibiotic regimen [32–34], which could lead to improved clinical outcomes [10].

Mistakes in identifying rarely encountered or phenotypically aberrant isolates are probably quite common in clinical microbiology laboratories. Sometimes, it is even difficult to know whether a bacterium has been incorrectly identified. For example, using phenotypic methods, *Francisella tularensis* subsp. *novicida* was consistently misidentified twice, as *Neisseria meningitidis* or *Actinobacillus actinomycetemcomitans* [35]. 16S rDNA sequencing will continue to play a major role in the identification of rare bacteria and bacteria with ambiguous characteristics in clinical microbiology laboratories.

*Identification of slow-growing bacteria.* 16S rDNA sequencing and similar molecular identification methods have the additional advantage of reducing the time required to identify slow-growing bacteria such as mycobacteria, which may take 6–8 weeks to grow in culture sufficiently for phenotypic tests to be performed. Even for rapidly growing mycobacteria, some biochemical reactions may take up to 28 days to complete. As for whole cell fatty acid analysis by gas chromatography, this requires special equipment and expertise that are often not available in clinical microbiology laboratories. Therefore, 16S rDNA sequencing has been used for identification of *Mycobacterium* species isolated from

clinical specimens, making clinical diagnosis more rapid and guiding prompt antibiotic treatment [29,36]. Using this technique, we were able to describe a novel clinical syndrome, acupuncture mycobacteriosis, caused by relatively alcohol-resistant mycobacteria in patients receiving acupuncture [37,38]. However, a limited number of mycobacterial species could not be differentiated from one another by 16S rDNA sequencing, e.g. *Mycobacterium avium intracellulare* and *M. paratuberculosis*, *M. chelonae* and *M. abscessus*, and members of the *M. tuberculosis* complex. Therefore, other gene targets, sometimes supplemented by phenotypic results, have to be used for differentiation of these species, e.g. *hsp65* and *rpoB* for those that grow rapidly, and 16S–23S rRNA internal transcribed spacer or *gyrB* for the mycobacteria that grow slowly [39–42].

*Routine identification.* Several studies have been conducted to compare the usefulness of 16S rDNA sequencing with conventional or commercial methods for the identification of various groups of medically important bacteria. In general, 16S rDNA sequencing results in a higher percentage of species identification than conventional or commercial methods. The success rate of species identification by 16S rDNA sequencing ranged from 62% to 92%, depending on the group of bacteria and the criteria used for species definition [43–49]. However, there are 'blind spots' within some major genera, in which 16S rDNA sequences are not sufficiently discriminative for the identification of certain species. In these circumstances, alternative targets have to be investigated. For example, *groEL* is a commonly used essential gene other than 16S rDNA which is useful for classification and identification of many groups of bacteria, e.g. staphylococci and *Burkholderia* species [50,51]. In particular, it has been shown to be useful in differentiating *Burkholderia pseudomallei* from *B. thailandensis*, the 16S rDNA sequences of which are indistinguishable [52,53]. Similarly, 16S rDNA sequencing has limited discriminatory power for closely related *Staphylococcus* species. Therefore, sequencing of *groEL* and *tuf* has been proposed as being more reliable for identification of coagulase-negative staphylococci [47,54].

As simple conventional methods are often available for commonly encountered bacteria,

16S rDNA sequencing for identification of 'routine' bacterial strains is most useful in the context of bacterial species that are often difficult to identify with phenotypic tests. This has led to a better understanding of the epidemiology and pathogenicity of these clinically 'unidentifiable' bacteria. One remarkable example is provided by anaerobic Gram-positive rods, where conventional methods are simply not reliable, even for genus identification; with the use of 16S rDNA sequencing, many previously undescribed or ignored anaerobic bacterial species were found to contribute to cases of bacteraemia [55–59]. With regard to streptococci, cases of  $\beta$ -haemolytic Lancefield group G streptococcus bacteraemia have been found to be almost exclusively caused by *S. dysgalactiae* subsp. *equisimilis* using 16S rDNA sequencing, although *S. canis* infections in dog owners have been reported rarely [60,61]. In another study, six cases of '*S. milleri*' endocarditis were attributed to *S. anginosus*, suggesting that *S. anginosus* had the highest propensity to cause infective endocarditis among the three species of the '*S. milleri* group' [62]. Using this 'state-of-the-art' technique, it was also found that *Haemophilus segnis* is an important cause of non-*H. influenzae* bacteraemia [19,63,64]. In addition, the use of 16S rDNA sequencing for clinically 'unidentifiable' bacteria could have clinical significance regarding the choice of antibiotic regimen as well as the duration of treatment. For example, we have previously reported a case of empyema thoracis caused by *Enterococcus cecorum* that was unidentified by conventional methods and three commercial identification systems. Unlike other *Enterococcus* species, the organism is known to be susceptible to cefotaxime and ceftriaxone. In this case, the use of 16S rDNA sequencing not only allowed continuation of cefotaxime as treatment for the patient, who responded very well, but also suggested that the bacterium's cephalosporin susceptibility could well be explained by its unique phylogenetic position, it being the ancestor of other *Enterococcus* species and more closely related to *Streptococcus* species [65]. In other instances, 16S rDNA sequencing has been particularly useful in differentiating between *Actinomyces* and non-*Actinomyces* anaerobic Gram-positive bacilli, which is often difficult in clinical microbiology laboratories [66–68]. A definitive diagnosis of actinomycosis is important, as a prolonged course of appropriate antibiotic

treatment (weeks to months) is indicated to prevent relapse.

### Novel bacterial genus and species discovery

During the process of bacterial identification, potential novel species will be encountered when there is a significant difference between the phenotypic characteristics and/or 16S rDNA sequences of the unknown bacterium and those of the most closely related ones. As no single test or gene sequence is ideal for the definition of new species in all groups of bacteria, a polyphasic approach is usually used when a novel species is defined. Depending on the group of bacteria, this involves various combinations of phenotypic characteristics, 16S rDNA sequences, sequences of other housekeeping genes, and DNA–DNA hybridization results. In this section, we review the novel species discovered from human specimens in the first 7 years of the 21st century (2001–2007) in the English literature.

According to the inclusion and exclusion criteria used in the present article, 215 novel species, 29 of which belonged to novel genera, have been discovered from human specimens in the past 7 years. Among these 215 novel species, 100 (15 of novel genera) have been found in four or more subjects (Table 1). Among these 100 novel species, there were four (4%) aerobic Gram-positive cocci, 30 (30%) aerobic Gram-positive rods, three (3%) aerobic Gram-negative cocci, 24 (24%) aerobic Gram-negative rods, four (4%) anaerobic Gram-positive cocci, ten (10%) anaerobic Gram-positive rods, one (1%) anaerobic Gram-negative coccus, 22 (22%) anaerobic Gram-negative rods, and two (2%) spirochaetes. The largest numbers of novel species discovered and isolated from four or more subjects were of the genera *Mycobacterium* ( $n = 12$ ) and *Nocardia* ( $n = 6$ ). The oral cavity/dental-related specimens ( $n = 19$ ) and the gastrointestinal tract specimens ( $n = 26$ ) were the most important for discovery and/or the most important reservoirs of novel species. This is in line with the huge diversity of potential novel bacterial species in the human oral cavity and gastrointestinal tract [69,70]. Among the 100 novel species, *S. sinensis*, *Laribacter hongkongensis*, *Clostridium hathewayi* and *Borrelia spielmanii* have been most thoroughly characterized, with the reservoirs and routes of transmission documented, and

*S. sinensis*, *L. hongkongensis* and *C. hathewayi* have been found globally [71–89], although most *Nocardia* and *Mycobacterium* species were probably from the environment, and most anaerobes were probably from the oral cavity and/or gastrointestinal tract.

In our opinion, novel bacterial species recovered from human specimens should be reported, even if only one well-characterized strain is available. Despite extensive investigations, a microbiological cause cannot be determined in approximately half of the patients with infectious disease. For some clinical syndromes, such as neutropenic fever, no microbiological cause can be found in up to 80% of patients who are believed to be suffering from infective causes [90,91]. For some other syndromes, e.g. acute gastroenteritis and community-acquired pneumonia, the cause was undetermined in *c.* 40% of patients [92,93]. Over the years, tremendous efforts have been made to determine the microorganisms associated with these 'unexplained infectious disease syndromes'. The discovery of novel aetiological agents responsible for 'unexplained infectious disease syndromes' relies quite heavily on the description of novel microbes. Although standard or unusual forms of known microbes are sometimes considered to be novel causes of 'unexplained infectious disease syndromes' [94,95], most of the novel causes are indeed previously undescribed microbes. There has been much debate on the number of strains of a particular bacterium required for description of a novel bacterial species, but our experience with the discovery and characterization of *L. hongkongensis* and *S. sinensis* suggests that any well-characterized strain of a novel bacterial species recovered from human specimens should be reported. Concerning *L. hongkongensis*, when the bacterium was first discovered, only one strain was obtained [76]. The description of the novel bacterium and the wide availability of molecular techniques, sophisticated databases and bioinformatics tools have made discovery of additional strains from other countries and rapid sharing of information possible [77]. This has led to rapid confirmation of its association with gastroenteritis and the determination of its reservoir [79]. In retrospect, if the first strain of *L. hongkongensis* had not been described, the demonstration of its association with

**Table 1.** Novel bacterial species discovered in four or more human subjects in the 21st century

Bacteria	Year of first publication	References	Associated diseases	Source of isolation			Reservoir/ source of infection
				Human		Non-human	
				Patients	Asymptomatic individuals		
Aerobic and facultative anaerobic Gram-positive cocci							
<i>Kytococcus schroeteri</i>	2002	[159–162]	Infective endocarditis, pneumonia	Blood, BAL, prosthetic valve, abscess pus	–	–	–
<i>Streptococcus oligofermentans</i>	2003	[163]	–	–	Dental plaque, saliva	–	–
<i>S. pseudoporcinus</i>	2006	[164]	–	Female genitourinary tract	–	–	–
<i>S. sinensis</i>	2002	[71–75]	Infective endocarditis	Blood	Saliva	–	Oral cavity
Aerobic and facultative anaerobic Gram-positive rods							
<i>Actinomyces cardiffensis</i>	2002	[165]	Postmastoidectomy brain and ear abscesses, jaw abscess, pericolic abscess, sinusitis, pelvic actinomycosis	Abscess pus, pleural fluid, antral washout, IUCD	–	–	–
<i>A. funkei</i>	2002	[166,167]	–	Blood, sternum, abdominal incision, neck-face, thorax, pelvis, IUCD, vagina/penis, brain/CSF, superficial soft tissue lesion	–	–	–
<i>Bifidobacterium scardovii</i>	2002	[168]	–	Blood, urine, hip	–	–	–
<i>Brevibacterium lutescens</i>	2003	[169]	Peritonitis	Peritoneal fluid, infected ear discharge, peritoneal dialysate fluid	–	Peptone preparation	–
<i>Brevibacterium paucivorans</i>	2001	[170]	–	CSF, groin abscess, blood, ear discharge, intravascular catheter, wound, groin swab	–	–	–
<i>Corynebacterium aurimucosum</i> (= <i>Corynebacterium nigricans</i> )	2002	[171–173]	Meningitis, uterine infection, UTI, vaginitis, placental infection, vulval ulcer, female urogenital tract infection	Cervix, bartholin gland, vagina, CSF, endometrium, placenta, urine, vulva, amniotic fluid, blood, vaginal swab, vaginal ulcer, vaginal-rectal swab	–	–	–
<i>Corynebacterium freneyi</i>	2001	[174,175]	Bacteraemia	Pus from toe, varicose ulcer, subcutaneous abscess fistula, blood	–	–	–
<i>Corynebacterium resistens</i>	2005	[176]	Bacteraemia, nosocomial pneumonia, cellulitis	Blood, bronchial aspirate, cellulitis aspirate	–	–	–
<i>Lactobacillus coleohominis</i>	2001	[177]	–	–	Vagina, urine, cervix	–	–
<i>Microbacterium paraoxydans</i>	2003	[178]	Catheter-related bacteraemia	Blood, bronchial aspirate	–	Vegetable	–
<i>Mycobacterium arupense</i>	2006	[179]	–	Respiratory specimen, gastrointestinal tract, various sterile sites, e.g. tendon, lymph node, lung biopsy, pleural fluid, surgical tissue, urine	–	–	Possibly environmental
<i>M. bolletii</i>	2006	[42]	Chronic pneumonia	Sputum, stomach aspirate	–	–	–
<i>M. canariasense</i>	2004	[180]	Catheter-related bacteraemia	Blood	–	–	–
<i>M. colombiense</i>	2006	[181]	–	Sputum, blood	–	–	–
<i>M. florentinum</i>	2005	[182]	Lymphadenopathy, pneumonia	Sputum, stool, lymph node, gastric aspirate, BAL	–	–	–
<i>M. holsaticum</i>	2002	[183,184]	–	Sputum, urine, gastric fluid	–	Lymph node of cattle with evidence of bovine tuberculosis	–
<i>M. immunogenum</i>	2001	[185–190]	Disseminated cutaneous infection, keratitis, catheter-related infection, septic arthritis, chronic pneumonia, pacemaker-related sepsis, hypersensitivity pneumonitis, chronic leg ulcer, peritonitis	Skin, cornea, urine, intravenous catheter site, joint fluid, BAL, blood, broviac site, leg biopsy, corneal scraping, peritoneal fluid of patients receiving IPD	–	Hospital environment, metalworking fluid, environment, tap water, water in IPD machines	Probably tap water
<i>M. massiliense</i>	2004	[191–193]	Pneumonia, post-intramuscular injection abscess, pacemaker pocket infection	Sputum, BAL, pus, tissue debris, specimen from surgical debridement, blood	–	–	–

Table 1. (continued)

Bacteria	Year of first publication	References	Associated diseases	Source of isolation			Reservoir/ source of infection
				Human		Non-human	
				Patients	Asymptomatic individuals		
<i>M. monacense</i>	2006	[194]	Post-traumatic wound infection	Biopsy, sputum, BAL	–	–	Possibly environmental
<i>M. nebraskense</i>	2004	[195,196]	Respiratory infection	Sputum, BAL	–	–	–
<i>M. palustre</i>	2002	[184,197]	Lymphadenitis	Submandibular lymph node biopsy	–	Submandibular lymph node of pig, stream water, lymph node of cattle with evidence of bovine tuberculosis	–
<i>M. saskatchewanense</i>	2004	[198]	Pneumonia in bronchiectasis patients	Sputum, pleural fluid, respiratory sample	–	–	–
<i>Nocardia africana</i>	2001	[199,200]	Pulmonary nocardiosis	Sputum	–	Subcutaneous nodule of cat	–
<i>N. aobensis</i>	2004	[201]	–	–	–	–	–
<i>N. arthritidis</i>	2004	[202,203]	Thigh abscess, pulmonary nocardiosis, keratitis	Sputum, thigh inflammatory swelling discharge, cornea	–	–	–
<i>N. asiatica</i>	2004	[203–205]	Pulmonary nocardiosis, skin infection, keratitis, ocular nocardiosis	Sputum, granuloma, transtracheal aspirate, cutaneous ulcer, cornea, vitreous body	–	–	Possibly environmental
<i>N. ignorata</i>	2001	[206–208]	Pulmonary nocardiosis	Sputum, BAL, blood, tracheal aspirate	–	Soil	Probably soil
<i>N. veterana</i>	2001	[209–215]	Pulmonary nocardiosis, mycetoma, bacteraemia, peritonitis	BAL, subcutaneous nodule biopsy, sputum, open lung biopsy tissue, fine-needle transthoracic biopsy and aspirate, blood, peritoneal fluid	–	–	–
<i>Olsenella profusa</i> <sup>a</sup>	2001	[216–218]	Periodontitis, acute periradicular abscess	Subgingival plaque, carious dental lesion, root canal, pus	–	–	–
<i>Weissella cibaria</i> (= <i>Weissella kimchii</i> )	2002	[219–225]	–	Gall	Stool	Ear of dog with otitis, cheese whey, sugar cane, canary liver, chili bo, tapai, wheat sourdough, blood sausage, faecal swab of healthy dog, plaa-som (fermented fish product from Thailand), fermented kimchii, whole crop paddy rice silage	–
Aerobic and facultative anaerobic Gram-negative cocci							
<i>Achromobacter insolitus</i>	2003	[226]	–	Urine, wound	–	Laboratory sink	–
<i>Achromobacter spanius</i>	2003	[226]	–	Blood	–	–	–
<i>Kerstersia gyjorum</i> <sup>a</sup>	2003	[227]	–	Stool, leg and ankle wounds, sputum	–	–	–
Aerobic and facultative anaerobic Gram-negative rods							
<i>Acinetobacter parvus</i>	2003	[228]	Catheter-related bacteraemia	Ear, eye, forehead, skin, blood	–	Ear of dog with refractory otitis media	–
<i>Acinetobacter schindleri</i>	2001	[229,230]	Cystitis, bacteraemia	Urine, vagina, throat, ear, nasal swab, conjunctiva, skin, pleural effusion, liquor, blood, central catheter	–	–	–
<i>Acinetobacter ursingii</i>	2001	[229–231]	Infective endocarditis, bacteraemia, UTI, postneurosurgical meningitis, cholangitis, cervical adenopathy	Blood, intravenous line, pus, ulcer, eye, wound, urine, hairy skin, toe, abscess, central catheter, ganglion biopsy, CSF	–	–	–
<i>Advenella incenata</i> <sup>a</sup>	2005	[232]	–	Sputum, blood	–	Horse blood	–

Table 1. (continued)

Bacteria	Year of first publication	References	Associated diseases	Source of isolation		Reservoir/ source of infection	
				Human			Non-human
				Patients	Asymptomatic individuals		
<i>Averyella dalhousiensis</i> <sup>a</sup>	2005	[233]	Catheter-related bacteraemia, cellulitis, wound infection	Wound, stool, blood, intestinal fluid	–	–	
<i>Burkholderia ambifaria</i>	2001	[234,235]	Keratitis	Sputum and respiratory tract of CF patients, corneal culture	–	Biocontrol strains; corn roots; corn, pea, snap bean and sedge rhizosphere; forest soil, leaves of <i>Sesbania exaltata</i> , commercial soil	
<i>B. fungorum</i>	2001	[236,237]	Septic arthritis	Vaginal secretion of pregnant woman, CSF, blood	–	White-rot fungus <i>Phanerochaete chrysosporium</i> , mouse nose, haemoglobin solution	
<i>Campylobacter hominis</i>	2001	[88,238,239]	Bacteraemia	Blood	Stool	–	
<i>Cardiobacterium valvarum</i>	2004	[240–244]	Infective endocarditis, prosthetic valve endocarditis	Blood, noma lesion	–	–	
<i>Cupriavidus respiraculi</i> (= <i>Wautersia respiraculi</i> = <i>Ralstonia respiraculi</i> )	2003	[245–247]	–	Sputum and respiratory tract of CF patients	–	–	
<i>Enterobacter ludwigii</i>	2005	[248]	Nosocomial UTI	Urine, trachea, fat tissue of left thigh, venous line, sputum, blood, stool, BAL, biopsy, throat, skin, swab	–	–	
<i>Escherichia albertii</i>	2003	[249]	Diarrhoea	Stool	–	–	
<i>Granulibacter bethesdensis</i> <sup>a</sup>	2006	[250,251]	Lymphadenitis in CGD patients	Lymph node	–	–	
<i>Haematobacter massiliensis</i> <sup>a</sup> (= <i>Rhodobacter massiliensis</i> )	2003	[252,253]	Bacteraemia, wound infection	Nose, blood, wound	–	–	
<i>Halomonas phocaensis</i>	2007	[254]	Fresh frozen plasma transfusion-associated bacteraemia/pseudo-bacteraemia	Blood	–	–	
<i>Helicobacter winghamensis</i>	2001	[255,256]	–	Stool of patients with gastroenteritis	–	Stool of gerbils	
<i>Inquilinus limosus</i> <sup>a</sup>	2002	[257–261]	Acute respiratory exacerbation and progressive loss of pulmonary function in CF patients?	Respiratory secretion and sputum of CF patients	–	Roots of grass	
<i>Laribacter hongkongensis</i> <sup>d</sup>	2001	[76–84, 262–265]	Bacteraemia, empyema thoracis, community-acquired gastroenteritis, travellers' diarrhoea	Blood, empyema pus, stool	–	Freshwater fish, drinking water reservoir	
<i>Neisseria bacilliformis</i>	2006	[266]	Wound infection, bronchitis, lung abscess	Ear, blood, oral fistula, submandibular wound, sputum, lung abscess	–	–	

gastroenteritis would have been hampered. Therefore, in the context of pathogenic microbes, we think that even one strain of a novel

species should be described, so that global, concerted efforts can be made to identify more cases associated with that pathogen.



Table 1. (continued)

Bacteria	Year of first publication	References	Associated diseases	Source of isolation		
				Human		Non-human
				Patients	Asymptomatic individuals	Reservoir/source of infection
<i>Paracoccus yeii</i>	2003	[267]	CAPD peritonitis, wound infection, biliary tract infection, bacteraemia	Abdominal dialysate, wound, bile, CSF, blood	-	-
<i>Pseudomonas mosseli</i>	2002	[268,269]	-	Tracheal aspirate, bronchial aspirate, blood, venous catheter, stool, drainage liquid	-	Mineral water
<i>P. otitidis</i>	2006	[270]	Acute otitis externa, acute otitis media, chronic suppurative otitis media	Ear of patients with acute otitis externa, acute otitis media, chronic suppurative otitis media	-	-
<i>Ralstonia taiwanensis</i>	2001	[271]	-	Sputum of CF patients	-	Root nodule of <i>Mimosa</i> species
<i>Wautersiella falsenii</i> <sup>a</sup>	2006	[272]	-	Blood, wound, pus, respiratory tract, ear discharge, vaginal swab, pleural fluid, oral cavity	-	-
Anaerobic Gram-positive cocci						
<i>Anaerococcus murdochii</i>	2007	[273]	Infected foot ulcer, infected sternal wound, soft tissue neck infection, post-traumatic thumb abscess	Wound, abscess	-	-
<i>Peptoniphilus gorbachii</i>	2007	[273]	Infected dry gangrene, cellulitis, infected diabetic foot ulcer	Wound	-	-
<i>Peptoniphilus olsenii</i>	2007	[273]	Osteomyelitis, infected dry gangrene, infected diabetic foot ulcer, toe infection	Bone, wound	-	-
<i>Peptostreptococcus stomatis</i>	2006	[274,275]	Dento-alveolar abscess, endodontic infection, pericoronal infection, bacteraemia	Specimen from infected structure of oral cavity, oropharyngeal specimen, appendix, stool, blood	-	Possibly oral cavity and gastrointestinal tract
Anaerobic Gram-positive rods						
<i>Alloscardovia omnicolens</i> <sup>a</sup>	2007	[276]	-	Urine, blood, urethra, oral cavity, tonsil, abscesses of lung and aortic valve	-	-
<i>Anaerostipes caccae</i> <sup>a</sup>	2002	[277,278]	-	-	Stool	Probably gastrointestinal tract
<i>Catabacter hongkongensis</i> <sup>a</sup>	2007	[59]	Bacteraemia	Blood	-	Probably gastrointestinal tract
<i>Clostridium bolteae</i>	2003	[279-281]	Bacteraemia, intra-abdominal abscess, necrotizing fasciitis, pelvic abscess, wound infection	Blood, intra-abdominal abscess, abscess, wound	Stool	Probably gastrointestinal tract
<i>C. hiranonis</i>	2001	[282,283]	-	-	Stool	Probably gastrointestinal tract
<i>Eggerthella hongkongensis</i>	2004	[55]	Perianal abscess, infected rectal tumour, liver abscess, appendicitis	Blood	-	Probably gastrointestinal tract
<i>Lactobacillus ultunensis</i>	2005	[284-286]	-	Cariou dentine	Gastric mucosa biopsy	Stool of pigs
<i>Roseburia intestinalis</i>	2002	[287]	-	-	Stool	Probably gastrointestinal tract
<i>Shuttleworthia satelles</i> <sup>a</sup>	2002	[288]	Periodontitis	Periodontal pocket, subgingival plaque	-	Probably oral cavity
<i>Varibaculum cambriensis</i> <sup>a</sup>	2003	[289]	Facial abscess, otogenic cerebral abscess	Abscess, IUCD	-	Possibly oral cavity
Anaerobic Gram-negative cocci						
<i>Veillonella montpellierensis</i>	2004	[290,291]	Infective endocarditis	Gastric fluid, amniotic fluid, blood	-	-
Anaerobic Gram-negative rods						
<i>Alistipes onderdonkii</i>	2006	[292]	Intra-abdominal infection	Appendix, abdominal abscess, stool, urine	Stool	Probably gastrointestinal tract
<i>Alistipes shahii</i>	2006	[292]	Intra-abdominal infection	Intra-abdominal fluid and appendix	Stool	Probably gastrointestinal tract
<i>Bacteroides intestinalis</i>	2006	[293]	-	-	Stool	Probably gastrointestinal tract

Table 1. (continued)

Bacteria	Year of first publication	References	Associated diseases	Source of isolation			Reservoir/ source of infection
				Human		Non-human	
				Patients	Asymptomatic individuals		
<i>Bacteroides plebeius</i>	2005	[294]	–	–	Stool	–	Probably gastrointestinal tract
<i>Cetobacterium somerae</i>	2003	[295]	–	–	Stool	–	Probably gastrointestinal tract
<i>Clostridium hathewayi</i> <sup>b</sup>	2001	[85–88]	Bacteraemic acute cholecystitis and liver abscess, bacteraemic acute gangrenous appendicitis, bacteraemia	Blood, liver abscess	Stool	–	Gastrointestinal tract
<i>Desulfomicrobium orale</i>	2001	[296]	Periodontitis	Subgingival plaque	–	–	Probably oral cavity
<i>Dialister invisus</i>	2003	[128, 297–299]	Endodontic and periodontal infections, UTI, acute periradicular abscess, acute periradicular periodontitis, acute apical abscess	Dental root canal, deep periodontal pocket, urine of renal transplant recipients, abscess pus, abscess aspirate	–	–	–
<i>Dialister microaerophilus</i>	2005	[300,301]	Anal, buttock, breast, perinephric abscess, bacteraemia, wound infection	Amniotic fluid, blood, pilonidal cyst, abscess pus, bone, bartholin gland, wound, phlegmon, skin and soft tissues, vagina	–	–	–
<i>Dialister propionificiens</i>	2005	[300]	Groin abscess, wound infection	Pressure ulcer, semen, abscess pus, wound	–	–	–
<i>Dysgonomonas mossii</i>	2002	[302,303]	–	Biliary drainage, abdominal drain, intestinal juice	–	–	–
<i>Leptotrichia amnionii</i>	2002	[304–307]	Septic arthritis, chorioamnionitis, renal abscess	Amniotic fluid, joint fluid, blood, renal abscess pus	–	–	Possibly female genital tract
<i>Parabacteroides goldsteinii</i> (= <i>Bacteroides goldsteinii</i> )	2005	[308,309]	Peritonitis, appendicitis, intra-abdominal abscess	Peritoneal fluid, appendix tissue, intra-abdominal abscess	–	–	Probably gastrointestinal tract
<i>Porphyromonas somerae</i>	2005	[310]	Chronic skin and soft tissue infections, osteomyelitis	Skin and soft tissues, bone	–	–	–
<i>Porphyromonas uenonis</i>	2004	[311]	Appendicitis, peritonitis, pilonidal abscess, infected sacral decubitus ulcer	Stool	–	–	Probably gastrointestinal tract
<i>Prevotella baroniae</i>	2005	[312]	Endodontic and periodontal infections, dentoalveolar abscess	Oral cavity	Dental plaque	–	–
<i>Prevotella bergensis</i>	2006	[313]	Skin and soft tissue abscesses, wound infection	Wound, decubitus ulcer	–	–	–
<i>Prevotella copri</i>	2007	[314]	–	–	Stool	–	Probably gastrointestinal tract
<i>Prevotella marshallii</i>	2005	[312]	Endodontic and periodontal infections	Oral cavity	Subgingival dental plaque	–	–
<i>Prevotella multififormis</i>	2005	[315]	Chronic periodontitis	Subgingival plaque	–	–	–
<i>Prevotella multisaccharivorax</i>	2005	[316]	Chronic periodontitis	Subgingival plaque	–	–	–
<i>Sneathia sanguinegens</i> <sup>a</sup>	2001	[317,318]	Postpartum bacteraemia	Blood, amniotic fluid	–	–	Probably female genital tract
Spirochetes							
<i>Borrelia spielmanii</i> (= <i>Borrelia spielmani</i> )	2004	[89]	Lyme disease	Erythema migrans lesion	–	Ticks	Garden dormice
<i>Treponema parvum</i>	2001	[319]	Periodontitis, acute necrotizing ulcerative gingivitis, acute and chronic apical periodontitis	Subgingival plaque, acute necrotizing ulcerative gingivitis lesion, root canal	–	–	–

<sup>a</sup>Also a novel genus.<sup>b</sup>The isolates discovered by Steer *et al.* were Gram-positive, but those found in the subsequent studies were Gram-negative.

BAL, bronchoalveolar lavage; IUCD, intrauterine contraceptive device; CSF, cerebrospinal fluid; UTI, urinary tract infection; CGD, chronic granulomatous disease; CF, cystic fibrosis; CAPD, continuous ambulatory peritoneal dialysis; IPD, intermittent peritoneal dialysis.

### Detection of uncultivable bacteria and diagnosis of culture-negative infections

Bacterial culture had been the most important technique for diagnosing bacterial infections since the first days of microbiology. Indeed, Koch's original postulates explicitly required that the pathogen be grown in a pure culture. This specific requirement has since been updated, and the clinical importance of 'uncultivable' bacteria, e.g. *Treponema pallidum*, is now well recognized. Nonetheless, given the central role of bacterial culture in most clinical laboratories, the diagnosis of culture-negative infections and those caused by uncultivable bacteria remains a somewhat arduous task. Direct microscopy and immunology-based assays have been the culture-independent methods traditionally used. The sensitivities and specificities of these methods can vary greatly, depending on the implementation and the organisms concerned. Direct microscopic examination demands a significant microbial presence in the specimen for positive identification, and serological tests suffer from cross-reactivities and may be affected by a patient's immunocompromised status. The introduction of molecular diagnostics significantly enhanced the ability to diagnose culture-negative infections. Among the various molecular assays available, 16S rDNA sequencing stands out as a useful technique for detecting uncultivable bacteria. The universal presence and sequence conservation of the gene allows broad-range PCR primers to be readily designed. This characteristic is of great importance, as it would be impractical to perform multiple specific assays to rule out individual bacteria associated with the disease.

An important use of 16S rDNA sequencing is the identification of clinical syndromes caused by uncultivable bacteria. These relate to infections caused by bacteria that could not be cultured reliably by known methods at the time of discovery. For example, Whipple's disease was known only as a systemic disorder of unknown aetiology when first described in 1907. Since then, gradual progress towards better diagnosis and treatment of the disease has been made, although the classic method of periodic acid-Schiff staining for diagnosis lacks both sensitivity and specificity when used alone. The first breakthrough in the understanding of Whipple's disease arrived with the identification of *Tropheryma whippeli* as the caus-

ative agent. This was accomplished by the PCR amplification and sequencing of its 16S rDNA gene [96,97]. The 16S rDNA sequence allowed the phylogenetic position of *T. whippeli* to be defined immediately, and enabled the later development of molecular diagnostic tests [97–100]. The definitive identification of the aetiological agent greatly accelerated research into the pathophysiology of the disease. In 2003, the genome sequences of two *T. whipplei* strains were completed [101,102], marking another milestone in medical history. Similar successes were seen in the context of bacillary angiomatosis (caused by *Bartonella henselae* and *Bartonella quintana*) [103,104] and human ehrlichiosis (caused by bacteria of the genera *Ehrlichia* and *Anaplasma*) [105–107].

16S rDNA sequencing has also been used for diagnosing culture-negative infections, the best example being culture-negative endocarditis. Up to one-third of all cases of infective endocarditis are culture-negative [108], and diagnosis has relied mainly upon clinical and ultrasonographic findings. Goldenberger *et al.* reported one of the earliest situations in which 16S rDNA PCR amplification and sequencing were performed on DNA extracted from infected valves [109]. Many subsequent studies confirmed the usefulness of the method [110–119]. In general, the sensitivity was found to be comparable to that of serological testing and histopathological examination. An interesting and important result of these studies is the recognition that many culture-negative cases were caused by cultivable Gram-positive bacteria, but the blood culture results might have been negative due to previous antibiotic usage. Other factors that may contribute to the false-negative blood culture results include inadequate microbiological techniques, e.g. use of an insufficient volume of blood, or infection by a fastidious organism [120].

Diagnosis of other culture-negative infections, including meningitis [121–125], brain abscess [126], keratitis [127], urinary tract infections [128], empyema [129,130], septic arthritis [131,132] and septicaemia [120,133,134], also benefits from the use of 16S rDNA sequencing. The encouraging results from these studies reinforced the idea that 16S rDNA sequencing is broadly applicable as a diagnostic technique in the context of clinical microbiology. Future developments should involve further optimization of universal primer sets and attempts to discriminate between

positive results and contamination or true pathogens. Recent progress in these areas has been made through the use of a broad-range real-time PCR design [124,135,136]. With continued improvements in performance and cost profile, 16S rDNA sequencing is expected to play an increasingly significant role in the diagnosis of culture-negative bacterial infections.

### Automation of 16S rDNA sequencing

One of the greatest hurdles in putting 16S rDNA sequencing into routine use in clinical microbiology laboratories is automation of the technology. At present, complete automation of 16S rDNA sequencing, i.e. input of the bacterial isolate/clinical sample for identification or its extracted DNA into a machine that will generate the result of the identity of the isolate, is impossible. Most of the steps, including DNA extraction, PCR amplification, purification of PCR products, DNA sequencing and sequence editing, have to be performed manually, although user-friendly commercial kits for some of these steps are available. With the advances in high-throughput technologies, these steps may be incorporated into a robotic system, making complete automation of 16S rDNA sequencing possible in the future.

At present, the only steps that can be automated are the input of the finalized 16S rDNA sequence concerned into one of the software packages that contains a database with 16S rDNA sequences of selected bacterial species and the output of the result of the identity of the isolate. The most well known of these software packages include Ribosomal Database Project (RDP-II) [137–141], MicroSeq [9,48,142,143], Ribosomal Differentiation of Medical Microorganisms (RIDOM) [144–146] and the SmartGene Integrated Database Network System (SmartGene IDNS) [147] (Table 2). The databases of RDP-II and SmartGene IDNS contain sequences downloaded from GenBank, whereas all sequences in the databases of RIDOM and MicroSeq were obtained by sequencing the 16S rDNA genes of bacterial strains of culture collections.

The major studies that have evaluated the usefulness of the various software packages for different groups of bacteria are summarized in Table 3. However, it is not possible to compare accuracy among the different studies, because

**Table 2.** Commonly used software packages for bacterial identification using 16S rDNA sequencing

Software	Year of first description	Company/Organization	Website	Partial/full 16S rDNA sequence included	Database size	Source of sequences	Cost	Quality control	Updates
RDP-II	1991	Michigan State University, USA	<a href="http://rdp.cme.msu.edu/">http://rdp.cme.msu.edu/</a>	Partial and full	>450 000 (release 9.56)	GenBank	No	Partial	Monthly
MicroSeq microbial identification system <sup>a</sup>	1998	Applied Biosystems, Foster City, CA, USA	<a href="http://www.microseq.com">http://www.microseq.com</a>	Partial and full <sup>b</sup>	1716 and 1261 in the two databases (version 2) respectively <sup>a</sup>	Sequence of 16S rDNA gene of one strain from each species	Yes	All type strains from culture collections	Periodically
RIDOM	1999	Ridom GmbH, Würzburg, Germany	<a href="http://rdna2.ridom.de/">http://rdna2.ridom.de/</a>	Partial	240 <sup>b</sup>	Sequence of 16S rDNA gene of bacteria in Neisseriaceae, Moraxellaceae and <i>Mycobacterium</i> <sup>c</sup>	No	All strains from culture collections	Periodically
SmartGene IDNS	2006	SmartGene GmbH, Switzerland	<a href="http://www.smartgene.ch/index.shtml">http://www.smartgene.ch/index.shtml</a>	Partial and full	~112 000 <sup>d</sup>	GenBank	Yes	Partial	Weekly

<sup>a</sup>It contains two databases, MicroSeq ID 16S rDNA 500 Library v2.0, which contains sequences from the 5'-end 527 bp of 16S rDNA genes, and MicroSeq ID 16S rDNA Full Gene Library v2.0, which contains full 16S rDNA sequences.

<sup>b</sup>Number counted from <http://rdna2.ridom.de/ridom2/servelet/link?page=list> (18 January, 2008).

<sup>c</sup>*Staphylococcus*, *Nozardtia* and *Bacillus* species were also studied [149,151,320] but were not found in the software database.

<sup>d</sup>Number obtained from reference [147].

**Table 3.** Studies on the usefulness of commonly used software packages for bacterial identification using 16S rDNA sequencing

References	Bacterial isolates tested	Methods for determination of real identity of the isolates	Accuracy of software
Tang <i>et al.</i> [10]	65 unusual aerobic Gram-negative bacilli from clinical specimens	Conventional phenotypic methods	MicroSeq 500: 89.2% (72% of 25 fermenters and 100% of 40 non-fermenters; 97.2% to genus level)
Tang <i>et al.</i> [143]	52 coryneform Gram-positive bacilli (42 <i>Corynebacterium</i> species and 10 <i>Corynebacterium</i> -related species) from clinical specimens	Conventional phenotypic methods <sup>a</sup>	MicroSeq 500: 66.7% <sup>a</sup> (100% to genus level)
Patel <i>et al.</i> [142]	113 <i>Mycobacterium</i> clinical isolates (18 different species)	Combination of phenotypic methods, 16S rDNA sequencing using the MicroSeq database, and other methods, e.g. standard biochemical assays, <i>hsp65</i> gene sequencing, AccuProbe rRNA hybridization, HPLC of mycolic acids. Identifications were counted as correct if two methods provided the same answer	MicroSeq 500 (version 1.36): 92.8% <sup>b</sup>
Turenne <i>et al.</i> [321]	79 non-tuberculous mycobacterial isolates (ATCC type strains)	Not described, but all were ATCC strains	BLAST (GenBank and EMBL databases, dated 30 March 2001): 38% <sup>c</sup> RDP-II (dated 30 March 2001): 41% <sup>c</sup> RIDOM (dated 8 March 2001): 100% <sup>c</sup>
Cloud <i>et al.</i> [148]	119 <i>Mycobacterium</i> isolates (94 clinical isolates and 25 ATCC strains)	Combination of conventional phenotypic methods, 16S rDNA sequencing using MicroSeq and RIDOM databases, and additional tests on problematic isolates	MicroSeq 500 (version 1.36) in conjunction with RIDOM database: 96.6% <sup>d</sup> (100% of 25 ATCC strains and 95.7% of 94 clinical isolates)
Mellmann <i>et al.</i> [149]	81 <i>Nocardia</i> clinical isolates	Combination of conventional phenotypic methods, 16S rDNA sequencing using MicroSeq and RIDOM databases	RIDOM (version 1.1): 100% <sup>e</sup> MicroSeq 500 (version 1.4.3, library version 500-0125): 44.4% <sup>e</sup>
Woo <i>et al.</i> [9]	37 (15 aerobic or facultative anaerobic Gram-positive; 11 aerobic, micro-aerophilic or facultative anaerobic Gram-negative, seven anaerobic; three mycobacterial; and one mycoplasma) clinical isolates with ambiguous biochemical profiles	Combination of phenotypic methods and full 16S rDNA sequencing	MicroSeq 500 (version 1.0): 81.1% (86.5% to genus level)
Hall <i>et al.</i> [43]	387 <i>Mycobacterium</i> isolates (59 ATCC strains and 328 clinical isolates)	Combination of conventional phenotypic methods, HPLC, PCR restriction analysis of 65-kDa heat shock protein region, 16S rDNA sequencing using MicroSeq 500 database	MicroSeq 500 (version 1.4.2): 68% (98.3% of 59 ATCC strains and 62.5% of 328 clinical isolates)
Cloud <i>et al.</i> [150]	94 <i>Nocardia</i> clinical isolates (ten separate species)	Combination of conventional phenotypic methods, 16S rDNA sequencing using expanded MicroSeq 500 database, restriction endonuclease assay for portions of 16S rDNA and <i>hsp65</i> genes, sequencing of a 999-bp fragment of the 16S rDNA gene	Expanded MicroSeq 500 (version 1.4.3, library version 500-0125) <sup>f</sup> : 82%
Becker <i>et al.</i> [151]	55 clinical <i>Staphylococcus</i> isolates	Combination of phenotypic methods, 16S rDNA sequencing using RIDOM and NCBI databases and additional tests (chemotaxonomy and ribotyping) on isolates with ambiguous or below the-threshold RIDOM results	RIDOM (version 1.2): 90.9% <sup>g</sup> GenBank (dated 12 January 2004): 65.5% <sup>g</sup>
Lau <i>et al.</i> [48]	20 anaerobic Gram-positive bacilli isolated from blood cultures	Preliminary phenotypic methods and full 16S rDNA sequencing	MicroSeq 500 (version 1.0): 65% (80% to genus level)
Patel <i>et al.</i> [322]	99 aerobic actinomycetes (28 reference strains and 71 clinical isolates, including members of the genera <i>Streptomyces</i> , <i>Gordonia</i> , and <i>Tsukamurella</i> , and ten taxa of <i>Nocardia</i> )	Phenotyping, PRA, drug susceptibility testing	MicroSeq 500: 70.3% <sup>h</sup> BLAST (GenBank): 70.3% <sup>i</sup>
Fontana <i>et al.</i> [152]	83 (25 Gram-positive and 58 Gram-negative) clinical isolates not identifiable by conventional systems	Not mentioned	Not determined
Simmon <i>et al.</i> [147]	300 (158 Gram-positive and 142 Gram-negative) clinical isolates	Combination of conventional phenotypic methods and 16S rDNA sequencing using SmartGene IDNS and MicroSeq 500 databases	SmartGene IDNS (version 3.2.3r8): 87% (98% to genus level) <sup>j</sup> MicroSeq 500 (version 1.4.3): 74% (90% to genus level) <sup>j</sup>

*hsp65*, heat shock protein 65; ATCC, American Type Culture Collection; BLAST, Basic Local Alignment Search Tool; EMBL, European Molecular Biology Laboratory; JCM, Japan Collection of Microorganisms; PRA, PCR-restriction endonuclease analysis.

<sup>a</sup>Four of the 52 isolates not identified by conventional phenotypic methods were not included.

<sup>b</sup>Two of the 113 isolates not identified by phenotypic methods were not included.

<sup>c</sup>Identification was considered correct if it was the best matched species, although not a perfect match. Over 1400 bp of the 16S gene was aligned in BLAST and RDP-II, whereas *Escherichia coli* bp 54–510 was used in RIDOM.

<sup>d</sup>Sequences resulting in distance score of <0.8%.

<sup>e</sup>Similarity >99.12% reported by either RIDOM or MicroSeq.

<sup>f</sup>An expanded portion of the database was developed from partial 5' 16S rDNA sequences derived from 28 reference strains (from ATCC and JCM); samples with 99–100% similarity to a species in the expanded MicroSeq 500 library were assigned that species designation, provided that the colony morphology and growth characteristics were consistent.

<sup>g</sup>Partial 16S rDNA fragment (corresponding to *E. coli* positions 54–510); classification is based on percentage similarity >98.5 to the 16S rDNA sequence of the type and reference strain.

<sup>h</sup>Eight of the 99 isolates not identified by phenotypic methods were not included. Eighty per cent of 30 *Actinomadura*, *Gordonia*, *Rhodococcus*, *Streptomyces* and *Tsukamurella* species, and 65.6% of 61 *Nocardia* species.

<sup>i</sup>Eight of the 99 isolates not identified by phenotypic methods were not included. Fifty per cent of 30 *Actinomadura*, *Gordonia*, *Rhodococcus*, *Streptomyces* and *Tsukamurella* species, and 80.3% of 61 *Nocardia* species.

<sup>j</sup>Genus-level and species-level identifications were assigned using the following criteria: >99% identity to a reference entry identified a bacterium to the species level, 97.0–98.9% identity identified a bacterium to the genus level, and <97% identity to any sequence was considered to be unable to provide a definite identification.

bacterial isolates from different sources (reference strains vs. clinical strains, identifiable strains vs. unidentified strains), different reference standards and different criteria for 'correct' identification were used in the different studies. In some studies, the identities of the isolates were determined by a combination of phenotypic and genotypic methods [43,142,147–151]. In others, such as a recent one on a heterogeneous group of clinical isolates, no reference standard was mentioned, except whether the isolates were 'identified' by MicroSeq [152]. As there are intrinsic problems with MicroSeq, e.g. inclusion of bacterial species with 16S rDNA sequences with minimal differences from those of some other species, it would be difficult for readers to assess the usefulness of MicroSeq from this study. As the intrinsic problems of the software packages may not be fully addressed in the publications, some of the reported accuracies of the software packages described may be overestimated.

#### USEFULNESS AND LIMITATIONS OF USING 16S RDNA SEQUENCING IN CLINICAL MICROBIOLOGY LABORATORIES

Although 16S rDNA sequencing is being used increasingly for bacterial identification in clinical microbiology laboratories, there are no widely accepted guidelines for using the technique or for the interpretation of sequence data. Given the limitations of the technique for some taxa, the ever-expanding sequence databases and taxonomic complexity, and the inaccuracies in some databases, some recommendations have been suggested for the use of 16S rDNA sequencing for bacterial identification [7,153]. For indications for the use of 16S rDNA sequencing, the strains most often chosen are those that cannot be accurately identified with phenotypic tests in clinical microbiology laboratories. However, as certain groups of bacteria are known to present difficulties in identification by 16S rDNA sequencing, these bacteria should be excluded, and other housekeeping gene targets, e.g. *rpoB*, if available, are required [39–42,47,50–54,153]. Regarding the interpretation of sequence data, this involves requirements concerning the length and quality of sequences, the choice of appropriate programs for analysis, and the final species assignment based on similarity search results. Although a

minimum of 500–525 bp that includes the more variable 5'-region may be adequate for identification of some groups of bacteria, Drancourt *et al.*, according to their several recommendations concerning the criteria for 16S rDNA sequencing as a reference method for bacterial identification, proposed that full 16S rDNA sequences with <1% ambiguities should be used [7]. The comparison should be made using at least 1500 positions in all sequences, of the same length, included in the similarity search, and an ungapped program should be used. In a recent review by Janda and Abbott, the use of full 16S rDNA sequences, whenever possible, and in particular for groups such as *Campylobacter* species [153], was confirmed as a viable technique.

The major difficulties and controversies in the interpretation of sequence data concern the assignment of bacterial species according to similarity search results, as no threshold values are available, as in the case of DNA–DNA hybridization [154]. Although a 97% similarity level has been proposed for bacterial speciation using 16S rDNA sequences [155], a >0.5% difference may be indicative of a new species [156]. In fact, as different bacterial species are likely to evolve at different rates, it is impossible to determine a universal cut-off for bacterial genus and species delineation. Although, in the study by Drancourt *et al.*, >99% and >97% sequence similarities were used as the cut-offs for species and genus identification, respectively, the authors indicated that these sharp values were set mainly for practical purposes, for interpretation of their large sequence dataset, and it may be necessary to use different cut-off values, depending on the bacterial genus under investigation [7]. On the other hand, Janda and Abbott, in their recommended guidelines, suggested that a minimum of >99%, and ideally >99.5%, sequence similarity be used as the criteria for species identification [153]. They also proposed that for matches with distance scores <0.5% to the next closest species, other properties, e.g. phenotype, should be considered in final species identification. However, using these criteria, it is difficult to determine the species identity with sequences that have very similar distances to the closest and next closest matches, especially those within 0.5–1%. Although different studies have identified groups of bacteria for which 16S rDNA sequences are not sufficiently discriminative and for which other

gene targets have to be used, very few studies have addressed and attempted to solve this problem in a systematic way.

The use of 16S rDNA sequencing for bacterial identification depends on significant interspecies differences and small intraspecies differences in 16S rDNA sequences. Therefore, one of the major limitations is that when two different bacterial species share almost the same 16S rDNA sequence, this technique would not be useful for distinguishing between them. In our experience, clinical microbiologists and technicians with limited experience in 16S rDNA sequencing often find interpretation of 16S rDNA similarity search results difficult. As a result of the large number of unvalidated 16S rDNA sequences in GenBank, it is not a straightforward task for inexperienced users to decide whether the 'first hit' or 'closest match' represents the actual identity of a bacterial isolate.

Regarding the software packages described above, the usefulness is further limited by the choice of bacterial species in the database. If a bacterial species is not included in the database, it would never be given as the identity of an isolate, and if the database also includes bacterial species with minimal differences in their 16S rDNA sequences and which, therefore, cannot be identified confidently by 16S rDNA sequencing, this may also give rise to incorrect identification.

In view of these limitations, we initiated a systematic evaluation of the potential usefulness of full and 527-bp 16S rDNA sequencing and the existing MicroSeq databases for identification of medically important bacteria 2 years ago. The species of medically important bacteria included in this analysis comprise all species of medically important bacteria listed in the *Manual of Clinical Microbiology* [157]. The most representative 16S rDNA sequence for each species was chosen from the GenBank database. The percentage differences of the 16S rDNA sequences among the different species in the same group/genus were determined by pairwise alignment.

The study first involved medically important anaerobic bacteria, and the results were published in 2007 [158]. Each medically important bacterial species is classified as one of the following: (i) the bacterium can be confidently identified by 16S rDNA sequencing (✓ in Table 4 and Supplementary Tables 2–4 of reference [158]), meaning that

**Table 4.** An example of guidelines for interpretation of usefulness of full 16S rDNA sequencing and MicroSeq full 16S rDNA bacterial identification system database for identification of medically important *Actinomyces* species (adapted from Supplementary Table 2 of reference [158] with permission)

<i>Actinomyces</i> species	Usefulness for species identification	Medically important bacteria with similar (<3% difference) full 16S rDNA gene sequences	Usefulness of existing MicroSeq full 16S rDNA bacterial identification system database
<i>A. bovis</i>	?	<i>A. urogenitalis</i>	? <sup>c</sup>
<i>A. bowdenii</i>	?	<i>A. viscosus</i>	× <sup>a</sup>
<i>A. canis</i>	✓		× <sup>a</sup>
<i>A. catuli</i>	✓		× <sup>a</sup>
<i>A. denticolens</i>	✓		× <sup>a</sup>
<i>A. europaei</i>	✓		× <sup>a</sup>
<i>A. funkei</i>	?	<i>A. hyovaginalis</i>	× <sup>a</sup>
<i>A. georgiae</i>	?	<i>A. meyeri</i>	× <sup>a</sup>
<i>A. gerencseriae</i>	✓		× <sup>a</sup>
<i>A. graevenitzi</i>	✓		× <sup>a</sup>
<i>A. hordeovulneris</i>	✓		× <sup>a</sup>
<i>A. howellii</i>	✓		✓
<i>A. hyovaginalis</i>	?	<i>A. funkei</i>	× <sup>a</sup>
<i>A. israelii</i>	✓		× <sup>a</sup>
<i>A. meyeri</i>	?	<i>A. georgiae</i> , <i>A. odontolyticus</i> , <i>A. turicensis</i>	? <sup>c</sup>
<i>A. naeslundii</i>	×	<i>A. viscosus</i>	× <sup>a</sup>
<i>A. neuii</i>	✓		✓
<i>A. odontolyticus</i>	×	<i>A. meyeri</i> , <i>A. turicensis</i>	× <sup>a</sup>
<i>A. radidentis</i>	✓		× <sup>a</sup>
<i>A. radingae</i>	✓		✓
<i>A. slackii</i>	✓		✓
<i>A. turicensis</i>	×	<i>A. meyeri</i> , <i>A. odontolyticus</i>	× <sup>a</sup>
<i>A. urogenitalis</i>	?	<i>A. bovis</i>	× <sup>a</sup>
<i>A. viscosus</i>	×	<i>A. bowdenii</i> , <i>A. naeslundii</i>	× <sup>b</sup>

✓, >3% difference between the 16S rDNA gene sequence of the species and those of other medically important bacteria; ?, 2–3% difference between the 16S rDNA gene sequence of the species and that of a closely related medically important bacterium; ×, <2% difference between the 16S rDNA gene sequence of the species and that of a closely related medically important bacterium.

<sup>a</sup>The species is not included in the existing MicroSeq full 16S rDNA bacterial identification system database.

<sup>b</sup>Although the species is included in the existing MicroSeq full 16S rDNA bacterial identification system database, the high 16S rDNA gene sequence similarity (>98% nucleotide identity) between the species and a closely related species does not allow them to be distinguished confidently.

<sup>c</sup>Although the species is included in the existing MicroSeq full 16S rDNA bacterial identification system database, a 2–3% difference is observed between the 16S rDNA gene of the species and a closely related species.

there is a >3% difference between the 16S rDNA sequence of the species and those of other medically important bacteria; (ii) the bacterium cannot be confidently identified by 16S rDNA sequencing (× in Table 4 and Supplementary Tables 2–4 of reference [158]), meaning that there is a <2% difference between the 16S rDNA sequence of the species and that of a closely related medically important bacterium; and (iii) the bacterium can only be doubtfully identified by 16S rDNA sequencing (? in Table 4 and Supplementary Tables 2–4 of reference [158]), meaning that there is a 2–3% difference between the 16S

rDNA sequence of the species and that of a closely related medically important bacterium. According to our guidelines for 16S rDNA sequence analysis, if the bacterium belongs to the '?' or 'x' category (e.g. *Actinomyces meyeri*; Table 4 and Supplementary Tables 2–4 of reference [158]), the bacterial species with similar 16S rDNA sequences will also be known (i.e. *A. georgiae*, *A. odontolyticus* and *A. turicensis*; Table 4 and Supplementary Tables 2–4 of reference [158]). If further species differentiation is necessary, one can look for additional/supplementary methods, which may be key phenotypic tests or sequencing of additional gene loci, to distinguish among these species with similar 16S rDNA sequences. It should be noted that the cut-offs mentioned are not meant to be used as criteria for defining new species, but to provide a clearer meaning for the search results.

Concerning MicroSeq database analysis, a supplementary note is given to indicate whether the reason for the inability of the database to identify the bacterium is due to the species being not included in the existing database ( $x^a$  in Table 4 and Supplementary Tables 2–4 of reference [158]), or high 16S rDNA sequence similarity (>98% nucleotide identity) to a closely related species ( $x^b$  in Table 4 and Supplementary Tables 2–4 of reference [158]). In the study on anaerobes, full and 527-bp 16S rDNA sequencing were capable of identifying 52–63% of 130 anaerobic Gram-positive rods, 72–73% of 86 anaerobic Gram-negative rods, and 78% of 23 anaerobic cocci. Surprisingly, the MicroSeq databases (version 1.0) were able to identify only 19–25% of 130 Gram-positive anaerobic rods, 38% of 86 Gram-negative anaerobic rods, and 39% of 23 anaerobic cocci. This represents only 45–46% of those that should be confidently identified by full-length and 527-bp 16S rDNA sequencing, indicating that, in order to improve the usefulness of MicroSeq, bacterial species that should be confidently identified by full-length and 527-bp 16S rDNA sequencing but are not included in the MicroSeq databases (version 1.0) should be included. Recently, there has been an expansion of the MicroSeq databases (version 2.0) to include more bacterial species, which has led to some improvement. At present, we are performing further studies of aerobic and facultative anaerobic Gram-positive and Gram-negative bacteria, and the results will be available in

the near future for the development of similar guidelines.

Despite the extensive analysis, there are still limitations in these guidelines. First, intraspecies variation in 16S rDNA sequences was not taken into account in the analysis. In the evaluation, only whether there was a significant difference between the 16S rDNA sequence of a particular species and those of other species was determined, and a 3% difference was chosen as the cut-off. Whether there is a high similarity among the 16S rDNA sequences in different strains of the same species is difficult to study, because: (i) 16S rDNA sequence information is available for multiple strains of the same species in only a minority of species; and (ii) even when 16S rDNA sequence information is available for multiple strains of the same species, the strains are often not well characterized phenotypically, so the reliability of the sequence information is difficult to judge. However, despite this limitation, a high degree of conservation of 16S rDNA sequences for the same species is often assumed, because most existing results do not indicate otherwise. On the other hand, for some genera, the intraspecies variation in 16S rDNA sequences may be so small that a difference of 3% in the 16S rDNA sequences between two species may not be necessary for confident identification. Second, the present study included only the bacterial species that are known to be associated with infections. This was deliberate, because, if those bacterial species that have never been reported to cause infections had also been included, some species may have been classified as 'not confidently identified by 16S rDNA sequencing' because of the sequence similarity between a bacterium and another that has never been reported to cause infection. One must bear in mind that those species that have never been reported to be associated with infections may still have the potential to do so. Owing to these limitations, we suggest that, in order to increase the accuracy of 16S rDNA sequencing for identification of pathogenic bacteria, it would be necessary to interpret the results of 16S rDNA sequencing with preliminary phenotypic test results. Nevertheless, our data not only facilitate interpretation of sequence data by inexperienced users in the clinical microbiology laboratories, but also provide clues to the potential usefulness of 16S rDNA



sequencing for different groups of bacteria before they are chosen for such analysis.

### CONCLUDING REMARKS

Not only has 16S rDNA sequencing contributed to answering some of the most fundamental questions in biology, but during the last decade this technology has evolved beyond the research realm and matured into clinical applications. For the management of individual patients, accurate and objective identification of clinical isolates, especially 'unidentifiable bacteria', rarely encountered bacteria, slow-growing bacteria and uncultivable bacteria, has assisted clinicians in the choice of antibiotics and in determining the duration of treatment, as well as in infection control measures. On a population scale, accurate identification has greatly improved our understanding of the epidemiology of clinical syndromes, and hence has improved empirical treatment of these. Our understanding of all these aspects is further improved by the discovery of novel genera and species of bacteria, which has been greatly facilitated by using 16S rDNA sequencing. Nevertheless, automation of 16S rDNA sequencing is not yet available and, despite the wide range of software packages and databases available, interpretation of results is often difficult for inexperienced users, due to their limitations. Hopefully, the generation of guidelines for the interpretation of 16S rDNA sequences can make this technology an even more user-friendly tool in clinical microbiology laboratories in the coming years.

### TRANSPARENCY DECLARATION

This work was partly supported by the Research Grant Council Grant, University Development Fund, Outstanding Young Researcher Award, HKU Special Research Achievement Award and The Croucher Senior Medical Research Fellowship, The University of Hong Kong. The authors declare no competing interests.

### REFERENCES

1. Fox GE, Magrum LJ, Balch WE, Wolfe RS, Woese CR. Classification of methanogenic bacteria by 16S ribosomal RNA characterization. *Proc Natl Acad Sci USA* 1977; **74**: 4537–4541.
2. Gupta R, Lanter JM, Woese CR. Sequence of the 16S ribosomal RNA from *Halobacterium volcanii*, an Archaeobacterium. *Science* 1983; **221**: 656–659.
3. Woese CR, Kandler O, Wheelis ML. Towards a natural system of organisms: proposal for the domains *Archaea*, *Bacteria*, and *Eucarya*. *Proc Natl Acad Sci USA* 1990; **87**: 4576–4579.
4. Snel B, Bork P, Huynen MA. Genome phylogeny based on gene content. *Nat Genet* 1999; **21**: 108–110.
5. Poyart C, Quesne G, Trieu-Cuot P. Taxonomic dissection of the *Streptococcus bovis* group by analysis of manganese-dependent superoxide dismutase gene (*sodA*) sequences: reclassification of '*Streptococcus infantarius* subsp. coli' as *Streptococcus lutetiensis* sp. nov. and of *Streptococcus bovis* biotype 11.2 as *Streptococcus pasteurianus* sp. nov. *Int J Syst Evol Microbiol* 2002; **52**: 1247–1255.
6. Arbique JC, Poyart C, Trieu-Cuot P *et al.* Accuracy of phenotypic and genotypic testing for identification of *Streptococcus pneumoniae* and description of *Streptococcus pseudopneumoniae* sp. nov. *J Clin Microbiol* 2004; **42**: 4686–4696.
7. Drancourt M, Bollet C, Carlioz A, Martelin R, Gayral JP, Raoult D. 16S ribosomal DNA sequence analysis of a large collection of environmental and clinical unidentifiable bacterial isolates. *J Clin Microbiol* 2000; **38**: 3623–3630.
8. Mignard S, Flandrois JP. 16S rRNA sequencing in routine bacterial identification: a 30-month experiment. *J Microbiol Methods* 2006; **67**: 574–581.
9. Woo PC, Ng KH, Lau SK *et al.* Usefulness of the MicroSeq 500 16S ribosomal DNA-based bacterial identification system for identification of clinically significant bacterial isolates with ambiguous biochemical profiles. *J Clin Microbiol* 2003; **41**: 1996–2001.
10. Tang YW, Ellis NM, Hopkins MK, Smith DH, Dodge DE, Persing DH. Comparison of phenotypic and genotypic techniques for identification of unusual aerobic pathogenic gram-negative bacilli. *J Clin Microbiol* 1998; **36**: 3674–3679.
11. Woo PC, Chong KT, Leung K, Que T, Yuen K. Identification of *Arcobacter cryaerophilus* isolated from a traffic accident victim with bacteremia by 16S ribosomal RNA gene sequencing. *Diagn Microbiol Infect Dis* 2001; **40**: 125–127.
12. Lau SK, Woo PC, Teng JL, Leung KW, Yuen KY. Identification by 16S ribosomal RNA gene sequencing of *Arcobacter butzleri* bacteraemia in a patient with acute gangrenous appendicitis. *Mol Pathol* 2002; **55**: 182–185.
13. Lau SK, Woo PC, Woo GK, Yuen KY. Catheter-related *Microbacterium* bacteremia identified by 16S rRNA gene sequencing. *J Clin Microbiol* 2002; **40**: 2681–2685.
14. Elshibly S, Xu J, McClurg RB *et al.* Central line-related bacteremia due to *Roseomonas mucosa* in a patient with diffuse large B-cell non-Hodgkin's lymphoma. *Leuk Lymphoma* 2005; **46**: 611–614.
15. Woo PC, Fung AM, Lau SK *et al.* *Granulicatella adiacens* and *Abiotrophia defectiva* bacteraemia characterized by 16S rRNA gene sequencing. *J Med Microbiol* 2003; **52**: 137–140.
16. Woo PC, Lau SK, Fung AM, Chiu SK, Yung RW, Yuen KY. *Gemella* bacteraemia characterised by 16S ribosomal RNA gene sequencing. *J Clin Pathol* 2003; **56**: 690–693.
17. Woo PC, Tse H, Wong SS *et al.* Life-threatening invasive *Helcococcus kunzii* infections in intravenous-drug users and *ermA*-mediated erythromycin resistance. *J Clin Microbiol* 2005; **43**: 6205–6208.

18. Lau SK, Woo PC, Woo GK *et al.* Bacteraemia caused by *Anaerotruncus colihominis* and emended description of the species. *J Clin Pathol* 2006; **59**: 748–752.
19. Somers CJ, Millar BC, Xu J *et al.* *Haemophilus segnis*: a rare cause of endocarditis. *Clin Microbiol Infect* 2003; **9**: 1048–1050.
20. Lau SK, Woo PC, Li NK *et al.* *Globicatella bacteraemia* identified by 16S ribosomal RNA gene sequencing. *J Clin Pathol* 2006; **59**: 303–307.
21. Lau SK, Teng JL, Leung KW *et al.* Bacteremia caused by *Solobacterium moorei* in a patient with acute proctitis and carcinoma of the cervix. *J Clin Microbiol* 2006; **44**: 3031–3034.
22. Woo PC, Lau SK, Lin AW, Curreem SO, Fung AM, Yuen KY. Surgical site abscess caused by *Lactobacillus fermentum* identified by 16S ribosomal RNA gene sequencing. *Diagn Microbiol Infect Dis* 2007; **58**: 251–254.
23. Weinstein MR, Litt M, Kertesz DA *et al.* Invasive infections due to a fish pathogen, *Streptococcus iniae*. *N Engl J Med* 1997; **337**: 589–594.
24. Lau SK, Woo PC, Tse H, Leung KW, Wong SS, Yuen KY. Invasive *Streptococcus iniae* infections outside North America. *J Clin Microbiol* 2003; **41**: 1004–1009.
25. Koh TH, Kurup A, Chen J. *Streptococcus iniae* discitis in Singapore. *Emerg Infect Dis* 2004; **10**: 1694–1696.
26. Lau SK, Woo PC, Luk WK *et al.* Clinical isolates of *Streptococcus iniae* from Asia are more mucoid and beta-hemolytic than those from North America. *Diagn Microbiol Infect Dis* 2006; **54**: 177–181.
27. Sun JR, Yan JC, Yeh CY, Lee SY, Lu JJ. Invasive infection with *Streptococcus iniae* in Taiwan. *J Med Microbiol* 2007; **56**: 1246–1249.
28. Woo PC, Leung KW, Tsoi HW, Wong SS, Teng JL, Yuen KY. Thermo-tolerant *Campylobacter fetus* bacteraemia identified by 16S ribosomal RNA gene sequencing: an emerging pathogen in immunocompromised patients. *J Med Microbiol* 2002; **51**: 740–746.
29. Woo PC, Tsoi HW, Leung KW *et al.* Identification of *Mycobacterium neoaurum* isolated from a neutropenic patient with catheter-related bacteremia by 16S rRNA sequencing. *J Clin Microbiol* 2000; **38**: 3515–3517.
30. Woo PC, Leung PK, Leung KW, Yuen KY. Identification by 16S ribosomal RNA gene sequencing of an Enterobacteriaceae species from a bone marrow transplant recipient. *Mol Pathol* 2000; **53**: 211–215.
31. Woo PC, Leung AS, Leung KW, Yuen KY. Identification of slide coagulase positive, tube coagulase negative *Staphylococcus aureus* by 16S ribosomal RNA gene sequencing. *Mol Pathol* 2001; **54**: 244–247.
32. Lefevre P, Gilot P, Godiscal H, Content J, Fauville-Dufaux M. *Mycobacterium intracellulare* as a cause of a recurrent granulomatous tenosynovitis of the hand. *Diagn Microbiol Infect Dis* 2000; **38**: 127–129.
33. Chen PL, Lee NY, Yan JJ *et al.* Prosthetic valve endocarditis caused by *Streptobacillus moniliformis*: a case of rat bite fever. *J Clin Microbiol* 2007; **45**: 3125–3126.
34. Woo PC, Cheung EY, Leung K, Yuen K. Identification by 16S ribosomal RNA gene sequencing of an Enterobacteriaceae species with ambiguous biochemical profile from a renal transplant recipient. *Diagn Microbiol Infect Dis* 2001; **39**: 85–93.
35. Clarridge JE 3rd, Raich TJ, Sjosted A *et al.* Characterization of two unusual clinically significant *Francisella* strains. *J Clin Microbiol* 1996; **34**: 1995–2000.
36. Heller R, Jaulhac B, Charles P *et al.* Identification of *Mycobacterium shimoides* in a tuberculosis-like cavity by 16S ribosomal DNA direct sequencing. *Eur J Clin Microbiol Infect Dis* 1996; **15**: 172–175.
37. Woo PC, Li JH, Tang W, Yuen K. Acupuncture mycobacteriosis. *N Engl J Med* 2001; **345**: 842–843.
38. Woo PC, Leung KW, Wong SS, Chong KT, Cheung EY, Yuen KY. Relatively alcohol-resistant mycobacteria are emerging pathogens in patients receiving acupuncture treatment. *J Clin Microbiol* 2002; **40**: 1219–1224.
39. Roth A, Fischer M, Hamid ME, Michalke S, Ludwig W, Mauch H. Differentiation of phylogenetically related slowly growing mycobacteria based on 16S–23S rRNA gene internal transcribed spacer sequences. *J Clin Microbiol* 1998; **36**: 139–147.
40. Ringuet H, Akoua-Koffi C, Honore S *et al.* *hsp65* sequencing for identification of rapidly growing mycobacteria. *J Clin Microbiol* 1999; **37**: 852–857.
41. Kasai H, Ezaki T, Harayama S. Differentiation of phylogenetically related slowly growing mycobacteria by their *gyrB* sequences. *J Clin Microbiol* 2000; **38**: 301–308.
42. Adekambi T, Berger P, Raoult D, Drancourt M. *rpoB* gene sequence-based characterization of emerging non-tuberculous mycobacteria with descriptions of *Mycobacterium bolletii* sp. nov., *Mycobacterium phocaicum* sp. nov. and *Mycobacterium aubagnense* sp. nov. *Int J Syst Evol Microbiol* 2006; **56**: 133–143.
43. Hall L, Doerr KA, Wohlfiel SL, Roberts GD. Evaluation of the MicroSeq system for identification of mycobacteria by 16S ribosomal DNA sequencing and its integration into a routine clinical mycobacteriology laboratory. *J Clin Microbiol* 2003; **41**: 1447–1453.
44. Bosshard PP, Abels S, Zbinden R, Bottger EC, Altwegg M. Ribosomal DNA sequencing for identification of aerobic gram-positive rods in the clinical laboratory (an 18-month evaluation). *J Clin Microbiol* 2003; **41**: 4134–4140.
45. Bosshard PP, Abels S, Altwegg M, Bottger EC, Zbinden R. Comparison of conventional and molecular methods for identification of aerobic catalase-negative gram-positive cocci in the clinical laboratory. *J Clin Microbiol* 2004; **42**: 2065–2073.
46. Song Y, Liu C, Bolanos M, Lee J, McTeague M, Finegold SM. Evaluation of 16S rRNA sequencing and reevaluation of a short biochemical scheme for identification of clinically significant *Bacteroides* species. *J Clin Microbiol* 2005; **43**: 1531–1537.
47. Heikens E, Fleer A, Paauw A, Florijn A, Fluit AC. Comparison of genotypic and phenotypic methods for species-level identification of clinical isolates of coagulase-negative staphylococci. *J Clin Microbiol* 2005; **43**: 2286–2290.
48. Lau SK, Ng KH, Woo PC *et al.* Usefulness of the MicroSeq 500 16S rDNA bacterial identification system for identification of anaerobic Gram positive bacilli isolated from blood cultures. *J Clin Pathol* 2006; **59**: 219–222.
49. Bosshard PP, Zbinden R, Abels S, Boddingtonhaus B, Altwegg M, Bottger EC. 16S rRNA gene sequencing versus the API 20 NE system and the VITEK 2 ID-GNB card for identification of nonfermenting Gram-negative bacteria in the clinical laboratory. *J Clin Microbiol* 2006; **44**: 1359–1366.
50. Kwok AY, Chow AW. Phylogenetic study of *Staphylococcus* and *Micrococcus* species based on partial *hsp60* gene sequences. *Int J Syst Evol Microbiol* 2003; **53**: 87–92.

51. Kwok AY, Su SC, Reynolds RP *et al.* Species identification and phylogenetic relationships based on partial HSP60 gene sequences within the genus *Staphylococcus*. *Int J Syst Bacteriol* 1999; **49** (Pt 3): 1181–1192.
52. Woo PC, Woo GK, Lau SK, Wong SS, Yuen K. Single gene target bacterial identification. *groEL* gene sequencing for discriminating clinical isolates of *Burkholderia pseudomallei* and *Burkholderia thailandensis*. *Diagn Microbiol Infect Dis* 2002; **44**: 143–149.
53. Woo PC, Lau SK, Woo GK *et al.* Seronegative bacteremic melioidosis caused by *Burkholderia pseudomallei* with ambiguous biochemical profile: clinical importance of accurate identification by 16S rRNA gene and *groEL* gene sequencing. *J Clin Microbiol* 2003; **41**: 3973–3977.
54. Goh SH, Potter S, Wood JO, Hemmingsen SM, Reynolds RP, Chow AW. HSP60 gene sequences as universal targets for microbial species identification: studies with coagulase-negative staphylococci. *J Clin Microbiol* 1996; **34**: 818–823.
55. Lau SK, Woo PC, Woo GK *et al.* *Eggerthella hongkongensis* sp. nov. and *Eggerthella sinensis* sp. nov., two novel *Eggerthella* species, account for half of the cases of *Eggerthella* bacteremia. *Diagn Microbiol Infect Dis* 2004; **49**: 255–263.
56. Lau SK, Woo PC, Fung AM, Chan KM, Woo GK, Yuen KY. Anaerobic, non-sporulating, Gram-positive bacilli bacteraemia characterised by 16S rRNA gene sequencing. *J Med Microbiol* 2004; **53**: 1247–1253.
57. Bosshard PP, Zbinden R, Altwegg M. *Turicibacter sanguinis* gen. nov., sp. nov., a novel anaerobic, Gram-positive bacterium. *Int J Syst Evol Microbiol* 2002; **52**: 1263–1266.
58. Woo PC, Lau SK, Chan KM, Fung AM, Tang BS, Yuen KY. *Clostridium* bacteraemia characterised by 16S ribosomal RNA gene sequencing. *J Clin Pathol* 2005; **58**: 301–307.
59. Lau SK, McNabb A, Woo GK *et al.* *Catabacter hongkongensis* gen. nov., sp. nov., isolated from blood cultures of patients from Hong Kong and Canada. *J Clin Microbiol* 2007; **45**: 395–401.
60. Woo PC, Fung AM, Lau SK, Wong SS, Yuen KY. Group G beta-hemolytic streptococcal bacteremia characterized by 16S ribosomal RNA gene sequencing. *J Clin Microbiol* 2001; **39**: 3147–3155.
61. Lam MM, Clarridge JE 3rd, Young EJ, Mizuki S. The other group G *Streptococcus*: increased detection of *Streptococcus canis* ulcer infections in dog owners. *J Clin Microbiol* 2007; **45**: 2327–2329.
62. Woo PC, Tse H, Chan KM *et al.* ‘*Streptococcus milleri*’ endocarditis caused by *Streptococcus anginosus*. *Diagn Microbiol Infect Dis* 2004; **48**: 81–88.
63. Lau SK, Woo PC, Mok MY *et al.* Characterization of *Haemophilus segnis*, an important cause of bacteremia, by 16S rRNA gene sequencing. *J Clin Microbiol* 2004; **42**: 877–880.
64. Lau SK, Woo PC, Chan BY, Fung AM, Que TL, Yuen KY. *Haemophilus segnis* polymicrobial and monomicrobial bacteraemia identified by 16S ribosomal RNA gene sequencing. *J Med Microbiol* 2002; **51**: 635–640.
65. Woo PC, Tam DM, Lau SK, Fung AM, Yuen KY. *Enterococcus cecorum* empyema thoracis successfully treated with cefotaxime. *J Clin Microbiol* 2004; **42**: 919–922.
66. Colmegna I, Rodriguez-Barradas M, Rauch R, Clarridge J, Young EJ. Disseminated *Actinomyces meyeri* infection resembling lung cancer with brain metastases. *Am J Med Sci* 2003; **326**: 152–155.
67. Woo PC, Fung AM, Lau SK, Yuen KY. Identification by 16S rRNA gene sequencing of *Lactobacillus salivarius* bacteremic cholecystitis. *J Clin Microbiol* 2002; **40**: 265–267.
68. Woo PC, Fung AM, Lau SK, Hon E, Yuen KY. Diagnosis of pelvic actinomycosis by 16S ribosomal RNA gene sequencing and its clinical significance. *Diagn Microbiol Infect Dis* 2002; **43**: 113–118.
69. Bik EM, Eckburg PB, Gill SR *et al.* Molecular analysis of the bacterial microbiota in the human stomach. *Proc Natl Acad Sci USA* 2006; **103**: 732–737.
70. Eckburg PB, Bik EM, Bernstein CN *et al.* Diversity of the human intestinal microbial flora. *Science* 2005; **308**: 1635–1638.
71. Woo PC, Tam DM, Leung KW *et al.* *Streptococcus sinensis* sp. nov., a novel species isolated from a patient with infective endocarditis. *J Clin Microbiol* 2002; **40**: 805–810.
72. Woo PC, Teng JL, Leung KW *et al.* *Streptococcus sinensis* may react with Lancefield group F antiserum. *J Med Microbiol* 2004; **53**: 1083–1088.
73. Woo PC, Teng JL, Lau SK, Yuen KY. Clinical, phenotypic, and genotypic evidence for *Streptococcus sinensis* as the common ancestor of *anginosus* and *mitis* groups of streptococci. *Med Hypotheses* 2006; **66**: 345–351.
74. Uckay I, Rohner P, Bolivar I *et al.* *Streptococcus sinensis* endocarditis outside Hong Kong. *Emerg Infect Dis* 2007; **13**: 1250–1252.
75. Faibis F, Mihaila L, Perna S *et al.* *Streptococcus sinensis*: an emerging agent of infective endocarditis. *J Med Microbiol* 2008; **57**: 528–531.
76. Yuen KY, Woo PC, Teng JL, Leung KW, Wong MK, Lau SK. *Laribacter hongkongensis* gen. nov., sp. nov., a novel gram-negative bacterium isolated from a cirrhotic patient with bacteremia and empyema. *J Clin Microbiol* 2001; **39**: 4227–4232.
77. Woo PC, Kuhnert P, Burnens AP *et al.* *Laribacter hongkongensis*: a potential cause of infectious diarrhea. *Diagn Microbiol Infect Dis* 2003; **47**: 551–556.
78. Lau SK, Woo PC, Hui WT *et al.* Use of cefoperazone MacConkey agar for selective isolation of *Laribacter hongkongensis*. *J Clin Microbiol* 2003; **41**: 4839–4841.
79. Woo PC, Lau SK, Teng JL *et al.* Association of *Laribacter hongkongensis* in community-acquired gastroenteritis with travel and eating fish: a multicentre case-control study. *Lancet* 2004; **363**: 1941–1947.
80. Teng JL, Woo PC, Ma SS *et al.* Ecoepidemiology of *Laribacter hongkongensis*, a novel bacterium associated with gastroenteritis. *J Clin Microbiol* 2005; **43**: 919–922.
81. Woo PC, Lau SK, Teng JL, Yuen KY. Current status and future directions for *Laribacter hongkongensis*, a novel bacterium associated with gastroenteritis and traveller’s diarrhoea. *Curr Opin Infect Dis* 2005; **18**: 413–419.
82. Lau SK, Woo PC, Fan RY, Lee RC, Teng JL, Yuen KY. Seasonal and tissue distribution of *Laribacter hongkongensis*, a novel bacterium associated with gastroenteritis, in retail freshwater fish in Hong Kong. *Int J Food Microbiol* 2007; **113**: 62–66.
83. Ni XP, Ren SH, Sun JR *et al.* *Laribacter hongkongensis* isolated from a patient with community-acquired gastroenteritis in Hangzhou City. *J Clin Microbiol* 2007; **45**: 255–256.
84. Lau SK, Woo PC, Fan RY *et al.* Isolation of *Laribacter hongkongensis*, a novel bacterium associated with gastro-

- enteritis, from drinking water reservoirs in Hong Kong. *J Appl Microbiol* 2007; **103**: 507–515.
85. Steer T, Collins MD, Gibson GR, Hippe H, Lawson PA. *Clostridium hathewayi* sp. nov., from human faeces. *Syst Appl Microbiol* 2001; **24**: 353–357.
  86. Elsayed S, Zhang K. Human infection caused by *Clostridium hathewayi*. *Emerg Infect Dis* 2004; **10**: 1950–1952.
  87. Woo PC, Lau SK, Woo GK, Fung AM, Yiu VP, Yuen KY. Bacteremia due to *Clostridium hathewayi* in a patient with acute appendicitis. *J Clin Microbiol* 2004; **42**: 5947–5949.
  88. Linscott AJ, Flamholtz RB, Shukla D, Song Y, Liu C, Finegold SM. Fatal septicemia due to *Clostridium hathewayi* and *Campylobacter hominis*. *Anaerobe* 2005; **11**: 97–98.
  89. Richter D, Schlee DB, Allgower R, Matuschka FR. Relationships of a novel Lyme disease spirochete, *Borrelia spielmani* sp. nov., with its hosts in Central Europe. *Appl Environ Microbiol* 2004; **70**: 6414–6419.
  90. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. *N Engl J Med* 1993; **328**: 1323–1332.
  91. Yuen KY, Woo PC, Hui CH *et al.* Unique risk factors for bacteraemia in allogeneic bone marrow transplant recipients before and after engraftment. *Bone Marrow Transplant* 1998; **21**: 1137–1143.
  92. Uhnöo I, Wadell G, Svensson L, Olding-Stenkvis E, Ekwall E, Molby R. Aetiology and epidemiology of acute gastro-enteritis in Swedish children. *J Infect* 1986; **13**: 73–89.
  93. Macfarlane JT, Colville A, Guion A, Macfarlane RM, Rose DH. Prospective study of aetiology and outcome of adult lower-respiratory-tract infections in the community. *Lancet* 1993; **341**: 511–514.
  94. Woo PC, Wong SS, Lum PN, Hui WT, Yuen KY. Cell-wall-deficient bacteria and culture-negative febrile episodes in bone-marrow-transplant recipients. *Lancet* 2001; **357**: 675–679.
  95. Woo PC, Ngan AH, Lau SK, Yuen KY. *Tsukamurella conjunctivitis*: a novel clinical syndrome. *J Clin Microbiol* 2003; **41**: 3368–3371.
  96. Wilson KH, Blitchington R, Frothingham R, Wilson JA. Phylogeny of the Whipple's-disease-associated bacterium. *Lancet* 1991; **338**: 474–475.
  97. Relman DA, Schmidt TM, MacDermott RP, Falkow S. Identification of the uncultured bacillus of Whipple's disease. *N Engl J Med* 1992; **327**: 293–301.
  98. Fenollar F, Raoult D. Molecular techniques in Whipple's disease. *Expert Rev Mol Diagn* 2001; **1**: 299–309.
  99. Fenollar F, Fournier PE, Raoult D, Gerolami R, Lepidi H, Poyart C. Quantitative detection of *Tropheryma whippelii* DNA by real-time PCR. *J Clin Microbiol* 2002; **40**: 1119–1120.
  100. Fenollar F, Fournier PE, Robert C, Raoult D. Use of genome selected repeated sequences increases the sensitivity of PCR detection of *Tropheryma whippelii*. *J Clin Microbiol* 2004; **42**: 401–403.
  101. Bentley SD, Maiwald M, Murphy LD *et al.* Sequencing and analysis of the genome of the Whipple's disease bacterium *Tropheryma whippelii*. *Lancet* 2003; **361**: 637–644.
  102. Raoult D, Ogata H, Audic S *et al.* *Tropheryma whippelii* Twist: a human pathogenic *Actinobacteria* with a reduced genome. *Genome Res* 2003; **13**: 1800–1809.
  103. Relman DA, Loutit JS, Schmidt TM, Falkow S, Tompkins LS. The agent of bacillary angiomatosis. An approach to the identification of uncultured pathogens. *N Engl J Med* 1990; **323**: 1573–1580.
  104. Regnery RL, Anderson BE, Clarridge JE 3rd, Rodriguez-Barradas MC, Jones DC, Carr JH. Characterization of a novel *Rochalimaea* species, *R. henselae* sp. nov., isolated from blood of a febrile, human immunodeficiency virus-positive patient. *J Clin Microbiol* 1992; **30**: 265–274.
  105. Maeda K, Markowitz N, Hawley RC, Ristic M, Cox D, McDade JE. Human infection with *Ehrlichia canis*, a leucocytic rickettsia. *N Engl J Med* 1987; **316**: 853–856.
  106. Anderson BE, Dawson JE, Jones DC, Wilson KH. *Ehrlichia chaffeensis*, a new species associated with human ehrlichiosis. *J Clin Microbiol* 1991; **29**: 2838–2842.
  107. Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic *Ehrlichia* species as the etiologic agent of human disease. *J Clin Microbiol* 1994; **32**: 589–595.
  108. Kupferwasser LI, Darius H, Muller AM *et al.* Diagnosis of culture-negative endocarditis: the role of the Duke criteria and the impact of transesophageal echocardiography. *Am Heart J* 2001; **142**: 146–152.
  109. Goldenberger D, Kunzli A, Vogt P, Zbinden R, Altwegg M. Molecular diagnosis of bacterial endocarditis by broad-range PCR amplification and direct sequencing. *J Clin Microbiol* 1997; **35**: 2733–2739.
  110. Wilck MB, Wu Y, Howe JG, Crouch JY, Edberg SC. Endocarditis caused by culture-negative organisms visible by Brown and Brenn staining: utility of PCR and DNA sequencing for diagnosis. *J Clin Microbiol* 2001; **39**: 2025–2027.
  111. Millar B, Moore J, Mallon P *et al.* Molecular diagnosis of infective endocarditis—a new Duke's criterion. *Scand J Infect Dis* 2001; **33**: 673–680.
  112. Gauduchon V, Chalabreysse L, Etienne J *et al.* Molecular diagnosis of infective endocarditis by PCR amplification and direct sequencing of DNA from valve tissue. *J Clin Microbiol* 2003; **41**: 763–766.
  113. Grijalva M, Horvath R, Dendis M, Erny J, Benedik J. Molecular diagnosis of culture negative infective endocarditis: clinical validation in a group of surgically treated patients. *Heart* 2003; **89**: 263–268.
  114. Bosshard PP, Kronenberg A, Zbinden R, Ruef C, Bottger EC, Altwegg M. Etiologic diagnosis of infective endocarditis by broad-range polymerase chain reaction: a 3-year experience. *Clin Infect Dis* 2003; **37**: 167–172.
  115. Lang S, Watkin RW, Lambert PA, Bonser RS, Littler WA, Elliott TS. Evaluation of PCR in the molecular diagnosis of endocarditis. *J Infect* 2004; **48**: 269–275.
  116. Lang S, Watkin RW, Lambert PA, Littler WA, Elliott TS. Detection of bacterial DNA in cardiac vegetations by PCR after the completion of antimicrobial treatment for endocarditis. *Clin Microbiol Infect* 2004; **10**: 579–581.
  117. Breittkopf C, Hammel D, Scheld HH, Peters G, Becker K. Impact of a molecular approach to improve the microbiological diagnosis of infective heart valve endocarditis. *Circulation* 2005; **111**: 1415–1421.
  118. Houpijian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. *Medicine (Baltimore)* 2005; **84**: 162–173.
  119. Kotilainen P, Heiro M, Jalava J *et al.* Aetiological diagnosis of infective endocarditis by direct amplification of rRNA genes from surgically removed valve tissue. An

- 11-year experience in a Finnish teaching hospital. *Ann Med* 2006; **38**: 263–273.
120. Cursons RT, Jeyerajah E, Sleigh JW. The use of polymerase chain reaction to detect septicemia in critically ill patients. *Crit Care Med* 1999; **27**: 937–940.
  121. Xu J, Millar BC, Moore JE *et al.* Employment of broad-range 16S rRNA PCR to detect aetiological agents of infection from clinical specimens in patients with acute meningitis—rapid separation of 16S rRNA PCR amplicons without the need for cloning. *J Appl Microbiol* 2003; **94**: 197–206.
  122. Schuurman T, de Boer RF, Kooistra-Smid AM, van Zwet AA. Prospective study of use of PCR amplification and sequencing of 16S ribosomal DNA from cerebrospinal fluid for diagnosis of bacterial meningitis in a clinical setting. *J Clin Microbiol* 2004; **42**: 734–740.
  123. Xu J, Moore JE, Millar BC, Webb H, Shields MD, Goldsmith CE. Employment of broad range 16S rDNA PCR and sequencing in the detection of aetiological agents of meningitis. *New Microbiol* 2005; **28**: 135–143.
  124. Deutch S, Pedersen LN, Podenphant L *et al.* Broad-range real time PCR and DNA sequencing for the diagnosis of bacterial meningitis. *Scand J Infect Dis* 2006; **38**: 27–35.
  125. Welinder-Olsson C, Dotevall L, Hogevik H *et al.* Comparison of broad-range bacterial PCR and culture of cerebrospinal fluid for diagnosis of community-acquired bacterial meningitis. *Clin Microbiol Infect* 2007; **13**: 879–886.
  126. Tsai JC, Teng LJ, Hsueh PR. Direct detection of bacterial pathogens in brain abscesses by polymerase chain reaction amplification and sequencing of partial 16S ribosomal deoxyribonucleic acid fragments. *Neurosurgery* 2004; **55**: 1154–1162.
  127. Knox CM, Cevallos V, Dean D. 16S ribosomal DNA typing for identification of pathogens in patients with bacterial keratitis. *J Clin Microbiol* 1998; **36**: 3492–3496.
  128. Domann E, Hong G, Imirzalioglu C *et al.* Culture-independent identification of pathogenic bacteria and polymicrobial infections in the genitourinary tract of renal transplant recipients. *J Clin Microbiol* 2003; **41**: 5500–5510.
  129. Saglani S, Harris KA, Wallis C, Hartley JC. Empyema: the use of broad range 16S rDNA PCR for pathogen detection. *Arch Dis Child* 2005; **90**: 70–73.
  130. Le Monnier A, Carbonnelle E, Zahar JR *et al.* Microbiological diagnosis of empyema in children: comparative evaluations by culture, polymerase chain reaction, and pneumococcal antigen detection in pleural fluids. *Clin Infect Dis* 2006; **42**: 1135–1140.
  131. Rosey AL, Abachin E, Quesnes G *et al.* Development of a broad-range 16S rDNA real-time PCR for the diagnosis of septic arthritis in children. *J Microbiol Methods* 2007; **68**: 88–93.
  132. Fihman V, Hannouche D, Bousson V *et al.* Improved diagnosis specificity in bone and joint infections using molecular techniques. *J Infect* 2007; **55**: 510–517.
  133. Sleigh J, Cursons R, La Pine M. Detection of bacteraemia in critically ill patients using 16S rDNA polymerase chain reaction and DNA sequencing. *Intensive Care Med* 2001; **27**: 1269–1273.
  134. Xu J, Moore JE, Millar BC *et al.* Improved laboratory diagnosis of bacterial and fungal infections in patients with hematological malignancies using PCR and ribosomal RNA sequence analysis. *Leuk Lymphoma* 2004; **45**: 1637–1641.
  135. Marin M, Munoz P, Sanchez M *et al.* Molecular diagnosis of infective endocarditis by real-time broad-range polymerase chain reaction (PCR) and sequencing directly from heart valve tissue. *Medicine (Baltimore)* 2007; **86**: 195–202.
  136. Schabereiter-Gurtner C, Nehr M, Apfalter P, Makrithathis A, Rotter ML, Hirschl AM. Evaluation of a protocol for molecular broad-range diagnosis of culture-negative bacterial infections in clinical routine diagnosis. *J Appl Microbiol*. 2008; **104**: 1228–1237.
  137. Maidak BL, Cole JR, Parker CT Jr *et al.* A new version of the RDP (Ribosomal Database Project). *Nucleic Acids Res* 1999; **27**: 171–173.
  138. Maidak BL, Cole JR, Lilburn TG *et al.* The RDP (Ribosomal Database Project) continues. *Nucleic Acids Res* 2000; **28**: 173–174.
  139. Maidak BL, Cole JR, Lilburn TG *et al.* The RDP-II (Ribosomal Database Project). *Nucleic Acids Res* 2001; **29**: 173–174.
  140. Cole JR, Chai B, Farris RJ *et al.* The Ribosomal Database Project (RDP-II): sequences and tools for high-throughput rRNA analysis. *Nucleic Acids Res* 2005; **33**: D294–D296.
  141. Cole JR, Chai B, Farris RJ *et al.* The ribosomal database project (RDP-II): introducing myRDP space and quality controlled public data. *Nucleic Acids Res* 2007; **35**: D169–D172.
  142. Patel JB, Leonard DG, Pan X, Musser JM, Berman RE, Nachamkin I. Sequence-based identification of *Mycobacterium* species using the MicroSeq 500 16S rDNA bacterial identification system. *J Clin Microbiol* 2000; **38**: 246–251.
  143. Tang YW, Von Graevenitz A, Waddington MG *et al.* Identification of coryneform bacterial isolates by ribosomal DNA sequence analysis. *J Clin Microbiol* 2000; **38**: 1676–1678.
  144. Harmsen D, Rothganger J, Singer C, Albert J, Frosch M. Intuitive hypertext-based molecular identification of micro-organisms. *Lancet* 1999; **353**: 291.
  145. Harmsen D, Rothganger J, Frosch M, Albert J. RIDOM: ribosomal differentiation of medical micro-organisms database. *Nucleic Acids Res* 2002; **30**: 416–417.
  146. Harmsen D, Dostal S, Roth A *et al.* RIDOM: comprehensive and public sequence database for identification of *Mycobacterium* species. *BMC Infect Dis* 2003; **3**: 26.
  147. Simmon KE, Croft AC, Petti CA. Application of Smart-Genes IDNS software to partial 16S rRNA gene sequences for a diverse group of bacteria in a clinical laboratory. *J Clin Microbiol* 2006; **44**: 4400–4406.
  148. Cloud JL, Neal H, Rosenberry R *et al.* Identification of *Mycobacterium* spp. by using a commercial 16S ribosomal DNA sequencing kit and additional sequencing libraries. *J Clin Microbiol* 2002; **40**: 400–406.
  149. Mellmann A, Cloud JL, Andrees S *et al.* Evaluation of RIDOM, MicroSeq, and Genbank services in the molecular identification of *Nocardia* species. *Int J Med Microbiol* 2003; **293**: 359–370.
  150. Cloud JL, Conville PS, Croft A, Harmsen D, Witebsky FG, Carroll KC. Evaluation of partial 16S ribosomal DNA sequencing for identification of nocardia species by using the MicroSeq 500 system with an expanded database. *J Clin Microbiol* 2004; **42**: 578–584.

151. Becker K, Harmsen D, Mellmann A *et al.* Development and evaluation of a quality-controlled ribosomal sequence database for 16S ribosomal DNA-based identification of *Staphylococcus* species. *J Clin Microbiol* 2004; **42**: 4988–4995.
152. Fontana C, Favaro M, Pelliccioni M, Pistoia ES, Favalli C. Use of the MicroSeq 500 16S rRNA gene-based sequencing for identification of bacterial isolates that commercial automated systems failed to identify correctly. *J Clin Microbiol* 2005; **43**: 615–619.
153. Janda JM, Abbott SL. 16S rRNA gene sequencing for bacterial identification in the diagnostic laboratory: pluses, perils, and pitfalls. *J Clin Microbiol* 2007; **45**: 2761–2764.
154. Petti CA. Detection and identification of microorganisms by gene amplification and sequencing. *Clin Infect Dis* 2007; **44**: 1108–1114.
155. Stackebrandt E, Goebel BM. Taxonomic note: a place for DNA–DNA reassociation and 16S rRNA sequence analysis in the present species definition in bacteriology. *Int J Syst Bacteriol* 1994; **44**: 846–849.
156. Palys T, Nakamura LK, Cohan FM. Discovery and classification of ecological diversity in the bacterial world: the role of DNA sequence data. *Int J Syst Bacteriol* 1997; **47**: 1145–1156.
157. Murray PR, Baron EJ, Jorgensen JH, Pfaller MA, Tenover FC, Tenover FC. *Manual of clinical microbiology*, 8th edn. Washington, DC: American Society for Microbiology, 2003.
158. Woo PC, Chung LM, Teng JL *et al.* *In silico* analysis of 16S ribosomal RNA gene sequencing-based methods for identification of medically important anaerobic bacteria. *J Clin Pathol* 2007; **60**: 576–579.
159. Becker K, Schumann P, Wullenweber J *et al.* *Kytococcus schroeteri* sp. nov., a novel Gram-positive actinobacterium isolated from a human clinical source. *Int J Syst Evol Microbiol* 2002; **52**: 1609–1614.
160. Le Brun C, Bouet J, Gautier P, Avril JL, Gaillot O. *Kytococcus schroeteri* endocarditis. *Emerg Infect Dis* 2005; **11**: 179–180.
161. Mohammedi I, Berchiche C, Becker K *et al.* Fatal *Kytococcus schroeteri* bacteremic pneumonia. *J Infect* 2005; **51**: E11–E13.
162. Mnif B, Boujelbene I, Mahjoubi F *et al.* Endocarditis due to *Kytococcus schroeteri*: case report and review of the literature. *J Clin Microbiol* 2006; **44**: 1187–1189.
163. Tong H, Gao X, Dong X. *Streptococcus oligofermentans* sp. nov., a novel oral isolate from caries-free humans. *Int J Syst Evol Microbiol* 2003; **53**: 1101–1104.
164. Bekal S, Gaudreau C, Laurence RA, Simoneau E, Raynal L. *Streptococcus pseudoporcinus* sp. nov., a novel species isolated from the genitourinary tract of women. *J Clin Microbiol* 2006; **44**: 2584–2586.
165. Hall V, Collins MD, Hutson R, Falsen E, Duerden BI. *Actinomyces cardiffensis* sp. nov. from human clinical sources. *J Clin Microbiol* 2002; **40**: 3427–3431.
166. Westling K, Lidman C, Thalme A. Tricuspid valve endocarditis caused by a new species of actinomyces: *Actinomyces funkei*. *Scand J Infect Dis* 2002; **34**: 206–207.
167. Smith AJ, Hall V, Thakker B, Gemmell CG. Antimicrobial susceptibility testing of *Actinomyces* species with 12 antimicrobial agents. *J Antimicrob Chemother* 2005; **56**: 407–409.
168. Hoyles L, Inganas E, Falsen E *et al.* *Bifidobacterium scardovii* sp. nov., from human sources. *Int J Syst Evol Microbiol* 2002; **52**: 995–999.
169. Wauters G, Avesani V, Laffineur K *et al.* *Brevibacterium lutescens* sp. nov., from human and environmental samples. *Int J Syst Evol Microbiol* 2003; **53**: 1321–1325.
170. Wauters G, Charlier J, Janssens M, Delmee M. *Brevibacterium paucivorans* sp. nov., from human clinical specimens. *Int J Syst Evol Microbiol* 2001; **51**: 1703–1707.
171. Yassin AF, Steiner U, Ludwig W. *Corynebacterium aurimucosum* sp. nov. and emended description of *Corynebacterium minutissimum* Collins and Jones (1983). *Int J Syst Evol Microbiol* 2002; **52**: 1001–1005.
172. Shukla SK, Bernard KA, Harney M, Frank DN, Reed KD. *Corynebacterium nigricans* sp. nov.: proposed name for a black-pigmented *Corynebacterium* species recovered from the human female urogenital tract. *J Clin Microbiol* 2003; **41**: 4353–4358.
173. Daneshvar MI, Hollis DG, Weyant RS *et al.* Identification of some charcoal-black-pigmented CDC fermentative coryneform group 4 isolates as *Rothia dentocariosa* and some as *Corynebacterium aurimucosum*: proposal of *Rothia dentocariosa* emend. Georg and Brown 1967, *Corynebacterium aurimucosum* emend. Yassin *et al.* 2002, and *Corynebacterium nigricans* Shukla *et al.* 2003 pro synonym. *Corynebacterium aurimucosum*. *J Clin Microbiol* 2004; **42**: 4189–4198.
174. Renaud FN, Aubel D, Riegel P, Meugnier H, Bollet C. *Corynebacterium freneyi* sp. nov., alpha-glucosidase-positive strains related to *Corynebacterium xerosis*. *Int J Syst Evol Microbiol* 2001; **51**: 1723–1728.
175. Auzias A, Bollet C, Ayari R, Drancourt M, Raoult D. *Corynebacterium freneyi* bacteremia. *J Clin Microbiol* 2003; **41**: 2777–2778.
176. Otsuka Y, Kawamura Y, Koyama T, Iihara H, Ohkusu K, Ezaki T. *Corynebacterium resistens* sp. nov., a new multidrug-resistant coryneform bacterium isolated from human infections. *J Clin Microbiol* 2005; **43**: 3713–3717.
177. Nikolaitchouk N, Wachter C, Falsen E, Andersch B, Collins MD, Lawson PA. *Lactobacillus coleohominis* sp. nov., isolated from human sources. *Int J Syst Evol Microbiol* 2001; **51**: 2081–2085.
178. Laffineur K, Avesani V, Cornu G *et al.* Bacteremia due to a novel *Microbacterium* species in a patient with leukemia and description of *Microbacterium paraoxydans* sp. nov. *J Clin Microbiol* 2003; **41**: 2242–2246.
179. Cloud JL, Meyer JJ, Pounder JI *et al.* *Mycobacterium arupense* sp. nov., a non-chromogenic bacterium isolated from clinical specimens. *Int J Syst Evol Microbiol* 2006; **56**: 1413–1418.
180. Jimenez MS, Campos-Herrero MI, Garcia D, Luquin M, Herrera L, Garcia MJ. *Mycobacterium canariensis* sp. nov. *Int J Syst Evol Microbiol* 2004; **54**: 1729–1734.
181. Murcia MI, Tortoli E, Menendez MC, Palenque E, Garcia MJ. *Mycobacterium colombiense* sp. nov., a novel member of the *Mycobacterium avium* complex and description of MAC-X as a new ITS genetic variant. *Int J Syst Evol Microbiol* 2006; **56**: 2049–2054.
182. Tortoli E, Rindi L, Goh KS *et al.* *Mycobacterium florentinum* sp. nov., isolated from humans. *Int J Syst Evol Microbiol* 2005; **55**: 1101–1106.

183. Richter E, Niemann S, Gloeckner FO, Pfyffer GE, Rusch-Gerdes S. *Mycobacterium holsaticum* sp. nov. *Int J Syst Evol Microbiol* 2002; **52**: 1991–1996.
184. Hughes MS, Ball NW, McCarroll J *et al.* Molecular analyses of mycobacteria other than the *M. tuberculosis* complex isolated from Northern Ireland cattle. *Vet Microbiol* 2005; **108**: 101–112.
185. Band JD, Ward JI, Fraser DW *et al.* Peritonitis due to a *Mycobacterium chelonae*-like organism associated with intermittent chronic peritoneal dialysis. *J Infect Dis* 1982; **145**: 9–17.
186. Wilson RW, Steingrube VA, Bottger EC *et al.* *Mycobacterium immunogenum* sp. nov., a novel species related to *Mycobacterium abscessus* and associated with clinical disease, pseudo-outbreaks and contaminated metal-working fluids: an international cooperative study on mycobacterial taxonomy. *Int J Syst Evol Microbiol* 2001; **51**: 1751–1764.
187. Wallace RJ Jr, Zhang Y, Wilson RW, Mann L, Rossmore H. Presence of a single genotype of the newly described species *Mycobacterium immunogenum* in industrial metalworking fluids associated with hypersensitivity pneumonitis. *Appl Environ Microbiol* 2002; **68**: 5580–5584.
188. Beckett W, Kallay M, Sood A, Zuo Z, Milton D. Hypersensitivity pneumonitis associated with environmental mycobacteria. *Environ Health Perspect* 2005; **113**: 767–770.
189. Loots MA, de Jong MD, van Soolingen D, Wetsteyn JC, Faber WR. Chronic leg ulcer caused by *Mycobacterium immunogenum*. *J Travel Med* 2005; **12**: 347–349.
190. Sampaio JL, Junior DN, de Freitas D *et al.* An outbreak of keratitis caused by *Mycobacterium immunogenum*. *J Clin Microbiol* 2006; **44**: 3201–3207.
191. Adekambi T, Reynaud-Gaubert M, Greub G *et al.* Amoebal culture of 'Mycobacterium massiliense' sp. nov. from the sputum of a patient with hemoptoic pneumonia. *J Clin Microbiol* 2004; **42**: 5493–5501.
192. Kim HY, Yun YJ, Park CG *et al.* Outbreak of *Mycobacterium massiliense* infection associated with intramuscular injections. *J Clin Microbiol* 2007; **45**: 3127–3130.
193. Simmon KE, Pounder JI, Greene JN *et al.* Identification of an emerging pathogen, *Mycobacterium massiliense*, by *rpoB* sequencing of clinical isolates collected in the United States. *J Clin Microbiol* 2007; **45**: 1978–1980.
194. Reischl U, Melzl H, Kroppenstedt RM *et al.* *Mycobacterium monacense* sp. nov. *Int J Syst Evol Microbiol* 2006; **56**: 2575–2578.
195. Mohamed AM, Iwen PC, Tarantolo S, Hinrichs SH. *Mycobacterium nebraskense* sp. nov., a novel slowly growing scotochromogenic species. *Int J Syst Evol Microbiol* 2004; **54**: 2057–2060.
196. Iwen PC, Tarantolo SR, Mohamed AM, Hinrichs SH. First report of *Mycobacterium nebraskense* as a cause of human infection. *Diagn Microbiol Infect Dis* 2006; **56**: 451–453.
197. Torkko P, Suomalainen S, Iivanainen E *et al.* *Mycobacterium palustre* sp. nov., a potentially pathogenic, slowly growing mycobacterium isolated from clinical and veterinary specimens and from Finnish stream waters. *Int J Syst Evol Microbiol* 2002; **52**: 1519–1525.
198. Turenne CY, Thibert L, Williams K *et al.* *Mycobacterium saskatchewanense* sp. nov., a novel slowly growing scotochromogenic species from human clinical isolates related to *Mycobacterium interjectum* and Accuprobe-positive for *Mycobacterium avium* complex. *Int J Syst Evol Microbiol* 2004; **54**: 659–667.
199. Hamid ME, Maldonado L, Sharaf Eldin GS, Mohamed MF, Saeed NS, Goodfellow M. *Nocardia africana* sp. nov., a new pathogen isolated from patients with pulmonary infections. *J Clin Microbiol* 2001; **39**: 625–630.
200. Hattori Y, Kano R, Kunitani Y, Yanai T, Hasegawa A. *Nocardia africana* isolated from a feline mycetoma. *J Clin Microbiol* 2003; **41**: 908–910.
201. Kageyama A, Suzuki S, Yazawa K, Nishimura K, Kroppenstedt RM, Mikami Y. *Nocardia aobensis* sp. nov., isolated from patients in Japan. *Microbiol Immunol* 2004; **48**: 817–822.
202. Kageyama A, Torikoe K, Iwamoto M *et al.* *Nocardia arthritidis* sp. nov., a new pathogen isolated from a patient with rheumatoid arthritis in Japan. *J Clin Microbiol* 2004; **42**: 2366–2371.
203. Yin X, Liang S, Sun X, Luo S, Wang Z, Li R. Ocular nocardiosis: HSP65 gene sequencing for species identification of *Nocardia* spp. *Am J Ophthalmol* 2007; **144**: 570–573.
204. Kageyama A, Poonwan N, Yazawa K, Mikami Y, Nishimura K. *Nocardia asiatica* sp. nov., isolated from patients with nocardiosis in Japan and clinical specimens from Thailand. *Int J Syst Evol Microbiol* 2004; **54**: 125–130.
205. Iona E, Giannoni F, Brunori L, de Gennaro M, Mattei R, Fattorini L. Isolation of *Nocardia asiatica* from cutaneous ulcers of a human immunodeficiency virus-infected patient in Italy. *J Clin Microbiol* 2007; **45**: 2088–2089.
206. Yassin AF, Rainey FA, Steiner U. *Nocardia ignorata* sp. nov. *Int J Syst Evol Microbiol* 2001; **51**: 2127–2131.
207. Kageyama A, Yazawa K, Ishikawa J, Hotta K, Nishimura K, Mikami Y. Nocardial infections in Japan from 1992 to 2001, including the first report of infection by *Nocardia transvalensis*. *Eur J Epidemiol* 2004; **19**: 383–389.
208. Rodriguez-Nava V, Couble A, Khan ZU *et al.* *Nocardia ignorata*, a new agent of human nocardiosis isolated from respiratory specimens in Europe and soil samples from Kuwait. *J Clin Microbiol* 2005; **43**: 6167–6170.
209. Gurtler V, Smith R, Mayall BC, Potter-Reinmann G, Stackebrandt E, Kroppenstedt RM. *Nocardia veterana* sp. nov., isolated from human bronchial lavage. *Int J Syst Evol Microbiol* 2001; **51**: 933–936.
210. Kano R, Hattori Y, Murakami N *et al.* The first isolation of *Nocardia veterana* from a human mycetoma. *Microbiol Immunol* 2002; **46**: 409–412.
211. Pottumarthy S, Limaye AP, Prentice JL, Houze YB, Swanzy SR, Cookson BT. *Nocardia veterana*, a new emerging pathogen. *J Clin Microbiol* 2003; **41**: 1705–1709.
212. Conville PS, Brown JM, Steigerwalt AG *et al.* *Nocardia veterana* as a pathogen in North American patients. *J Clin Microbiol* 2003; **41**: 2560–2568.
213. Godreuil S, Didelot MN, Perez C *et al.* *Nocardia veterana* isolated from ascitic fluid of a patient with human immunodeficiency virus infection. *J Clin Microbiol* 2003; **41**: 2768–2773.
214. Ansari SR, Safdar A, Han XY, O'Brien S. *Nocardia veterana* bloodstream infection in a patient with cancer and a summary of reported cases. *Int J Infect Dis* 2006; **10**: 483–486.
215. Agterof MJ, van der Bruggen T, Tersmette M, ter Borg EJ, van den Bosch JM, Biesma DH. Nocardiosis: a case series and a mini review of clinical and microbiological features. *Neth J Med* 2007; **65**: 199–202.

216. Dewhirst FE, Paster BJ, Tzellas N *et al.* Characterization of novel human oral isolates and cloned 16S rDNA sequences that fall in the family Coriobacteriaceae: description of *Olsenella* gen. nov., reclassification of *Lactobacillus uli* as *Olsenella uli* comb. nov. and description of *Olsenella profusa* sp. nov. *Int J Syst Evol Microbiol* 2001; **51**: 1797–1804.
217. Munson MA, Banerjee A, Watson TF, Wade WG. Molecular analysis of the microflora associated with dental caries. *J Clin Microbiol* 2004; **42**: 3023–3029.
218. Rocas IN, Siqueira JF Jr. Species-directed 16S rRNA gene nested PCR detection of *Olsenella* species in association with endodontic diseases. *Lett Appl Microbiol* 2005; **41**: 12–16.
219. Bjorkroth KJ, Schillinger U, Geisen R *et al.* Taxonomic study of *Weissella confusa* and description of *Weissella cibaria* sp. nov., detected in food and clinical samples. *Int J Syst Evol Microbiol* 2002; **52**: 141–148.
220. Choi HJ, Cheigh CI, Kim SB *et al.* *Weissella kimchii* sp. nov., a novel lactic acid bacterium from kimchi. *Int J Syst Evol Microbiol* 2002; **52**: 507–511.
221. De Vuyst L, Schrijvers V, Paramithiotis S *et al.* The biodiversity of lactic acid bacteria in Greek traditional wheat sourdoughs is reflected in both composition and metabolite formation. *Appl Environ Microbiol* 2002; **68**: 6059–6069.
222. Ennahar S, Cai Y, Fujita Y. Phylogenetic diversity of lactic acid bacteria associated with paddy rice silage as determined by 16S ribosomal DNA analysis. *Appl Environ Microbiol* 2003; **69**: 444–451.
223. Santos EM, Jaime I, Rovira J, Lyhs U, Korkeala H, Bjorkroth J. Characterization and identification of lactic acid bacteria in ‘morcilla de Burgos’. *Int J Food Microbiol* 2005; **97**: 285–296.
224. Graef EM, Devriese LA, Baele M *et al.* Identification of enterococcal, streptococcal and *Weissella* species in the faecal flora of individually owned dogs. *J Appl Microbiol* 2005; **99**: 348–353.
225. Sriannual S, Yanagida F, Lin LH, Hsiao KN, Chen YS. Weissellicin 110, a newly discovered bacteriocin from *Weissella cibaria* 110, isolated from plaasom, a fermented fish product from Thailand. *Appl Environ Microbiol* 2007; **73**: 2247–2250.
226. Coenye T, Vancanneyt M, Falsen E, Swings J, Vandamme P. *Achromobacter insolitus* sp. nov. and *Achromobacter spanius* sp. nov., from human clinical samples. *Int J Syst Evol Microbiol* 2003; **53**: 1819–1824.
227. Coenye T, Vancanneyt M, Cnockaert MC, Falsen E, Swings J, Vandamme P. *Kerstesia gyiorum* gen. nov., sp. nov., a novel *Alcaligenes faecalis*-like organism isolated from human clinical samples, and reclassification of *Alcaligenes denitrificans* Ruger and Tan 1983 as *Achromobacter denitrificans* comb. nov. *Int J Syst Evol Microbiol* 2003; **53**: 1825–1831.
228. Nemec A, Dijkshoorn L, Cleenwerck I *et al.* *Acinetobacter parvus* sp. nov., a small-colony-forming species isolated from human clinical specimens. *Int J Syst Evol Microbiol* 2003; **53**: 1563–1567.
229. Nemec A, De Baere T, Tjernberg I, Vaneechoutte M, van der Reijden TJ, Dijkshoorn L. *Acinetobacter ursingii* sp. nov. and *Acinetobacter schindleri* sp. nov., isolated from human clinical specimens. *Int J Syst Evol Microbiol* 2001; **51**: 1891–1899.
230. Dortet L, Legrand P, Soussy CJ, Cattoir V. Bacterial identification, clinical significance, and antimicrobial susceptibilities of *Acinetobacter ursingii* and *Acinetobacter schindleri*, two frequently misidentified opportunistic pathogens. *J Clin Microbiol* 2006; **44**: 4471–4478.
231. Loubinoux J, Mihaila-Amrouche L, Le Fleche A *et al.* Bacteremia caused by *Acinetobacter ursingii*. *J Clin Microbiol* 2003; **41**: 1337–1338.
232. Coenye T, Vanlaere E, Samyn E, Falsen E, Larsson P, Vandamme P. *Advenella incenata* gen. nov., sp. nov., a novel member of the Alcaligenaceae, isolated from various clinical samples. *Int J Syst Evol Microbiol* 2005; **55**: 251–256.
233. Johnson AS, Tarr CL, Brown BH Jr, Birkhead KM, Farmer JJ 3rd. First case of septicemia due to a strain belonging to enteric group 58 (*Enterobacteriaceae*) and its designation as *Averyella dalhousiensis* gen. nov., sp. nov., based on analysis of strains from 20 additional cases. *J Clin Microbiol* 2005; **43**: 5195–5201.
234. Coenye T, Mahenthalingam E, Henry D *et al.* *Burkholderia ambifaria* sp. nov., a novel member of the *Burkholderia cepacia* complex including biocontrol and cystic fibrosis-related isolates. *Int J Syst Evol Microbiol* 2001; **51**: 1481–1490.
235. Matoba AY. Polymicrobial keratitis secondary to *Burkholderia ambifaria*, *Enterococcus*, and *Staphylococcus aureus* in a patient with herpetic stromal keratitis. *Am J Ophthalmol* 2003; **136**: 748–749.
236. Coenye T, Laevens S, Willems A *et al.* *Burkholderia fungorum* sp. nov. and *Burkholderia caledonica* sp. nov., two new species isolated from the environment, animals and human clinical samples. *Int J Syst Evol Microbiol* 2001; **51**: 1099–1107.
237. Gerrits GP, Klaassen C, Coenye T, Vandamme P, Meis JF. *Burkholderia fungorum* septicemia. *Emerg Infect Dis* 2005; **11**: 1115–1117.
238. Lawson AJ, Linton D, Stanley J. 16S rRNA gene sequences of ‘*Candidatus Campylobacter hominis*’, a novel uncultivated species, are found in the gastrointestinal tract of healthy humans. *Microbiology* 1998; **144** (Pt 8): 2063–2071.
239. Lawson AJ, On SL, Logan JM, Stanley J. *Campylobacter hominis* sp. nov., from the human gastrointestinal tract. *Int J Syst Evol Microbiol* 2001; **51**: 651–660.
240. Paster BJ, Falkler WA Jr, Enwonwu CO *et al.* Prevalent bacterial species and novel phylotypes in advanced noma lesions. *J Clin Microbiol* 2002; **40**: 2187–2191.
241. Han XY, Meltzer MC, Woods JT, Fainstein V. Endocarditis with ruptured cerebral aneurysm caused by *Cardiobacterium valvarum* sp. nov. *J Clin Microbiol* 2004; **42**: 1590–1595.
242. Hoover SE, Fischer SH, Shaffer R, Steinberg BM, Lucey DR. Endocarditis due to a novel *Cardiobacterium* species. *Ann Intern Med* 2005; **142**: 229–230.
243. Bothelo E, Gouriet F, Fournier PE *et al.* Endocarditis caused by *Cardiobacterium valvarum*. *J Clin Microbiol* 2006; **44**: 657–658.
244. Geissdorfer W, Tandler R, Schlundt C, Weyand M, Daniel WG, Schoerner C. Fatal bioprosthetic aortic valve endocarditis due to *Cardiobacterium valvarum*. *J Clin Microbiol* 2007; **45**: 2324–2326.
245. Coenye T, Vandamme P, LiPuma JJ. *Ralstonia respiraculi* sp. nov., isolated from the respiratory tract of cystic



- fibrosis patients. *Int J Syst Evol Microbiol* 2003; **53**: 1339–1342.
246. Vaneechoutte M, Kampfer P, De Baere T, Falsen E, Verschraegen G. *Wautersia* gen. nov., a novel genus accommodating the phylogenetic lineage including *Ralstonia eutropha* and related species, and proposal of *Ralstonia* [*Pseudomonas*] *syzygii* (Roberts *et al.* 1990) comb. nov. *Int J Syst Evol Microbiol* 2004; **54**: 317–327.
247. Vandamme P, Coenye T. Taxonomy of the genus *Cupriavidus*: a tale of lost and found. *Int J Syst Evol Microbiol* 2004; **54**: 2285–2289.
248. Hoffmann H, Stindl S, Stumpf A *et al.* Description of *Enterobacter ludwigii* sp. nov., a novel *Enterobacter* species of clinical relevance. *Syst Appl Microbiol* 2005; **28**: 206–212.
249. Huys G, Cnockaert M, Janda JM, Swings J. *Escherichia albertii* sp. nov., a diarrhoeagenic species isolated from stool specimens of Bangladeshi children. *Int J Syst Evol Microbiol* 2003; **53**: 807–810.
250. Greenberg DE, Porcella SF, Stock F *et al.* *Granulibacter bethesdensis* gen. nov., sp. nov., a distinctive pathogenic acetic acid bacterium in the family *Acetobacteraceae*. *Int J Syst Evol Microbiol* 2006; **56**: 2609–2616.
251. Greenberg DE, Porcella SF, Zelazny AM *et al.* Genome sequence analysis of the emerging human pathogenic acetic acid bacterium *Granulibacter bethesdensis*. *J Bacteriol* 2007; **189**: 8727–8736.
252. Greub G, Raoult D. *Rhodobacter massiliensis* sp. nov., a new amoebae-resistant species isolated from the nose of a patient. *Res Microbiol* 2003; **154**: 631–635.
253. Hesel LO, Hollis D, Steigerwalt AG *et al.* Identification of 'Haematobacter', a new genus of aerobic Gram-negative rods isolated from clinical specimens, and reclassification of *Rhodobacter massiliensis* as 'Haematobacter massiliensis' comb. nov.'. *J Clin Microbiol* 2007; **45**: 1238–1243.
254. Berger P, Barguelli F, Raoult D, Drancourt M. An outbreak of *Halomonas phocaeensis* sp. nov. bacteraemia in a neonatal intensive care unit. *J Hosp Infect* 2007; **67**: 79–85.
255. Melito PL, Munro C, Chipman PR, Woodward DL, Booth TF, Rodgers FG. *Helicobacter winghamensis* sp. nov., a novel *Helicobacter* sp. isolated from patients with gastroenteritis. *J Clin Microbiol* 2001; **39**: 2412–2417.
256. Goto K, Jiang W, Zheng Q *et al.* Epidemiology of *Helicobacter* infection in wild rodents in the Xinjiang-Uygur autonomous region of China. *Curr Microbiol* 2004; **49**: 221–223.
257. Coenye T, Goris J, Spilker T, Vandamme P, LiPuma JJ. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of *Inquilinus limosus* gen. nov., sp. nov. *J Clin Microbiol* 2002; **40**: 2062–2069.
258. Wellinghausen N, Essig A, Sommerburg O. *Inquilinus limosus* in patients with cystic fibrosis, Germany. *Emerg Infect Dis* 2005; **11**: 457–459.
259. Schmoldt S, Latzin P, Heesemann J, Griese M, Imhof A, Hogardt M. Clonal analysis of *Inquilinus limosus* isolates from six cystic fibrosis patients and specific serum antibody response. *J Med Microbiol* 2006; **55**: 1425–1433.
260. Chowdhury SP, Schmid M, Hartmann A, Tripathi AK. Identification of diazotrophs in the culturable bacterial community associated with roots of *Lasiurus sindicus*, a perennial grass of Thar Desert, India. *Microb Ecol* 2007; **54**: 82–90.
261. Herasimenka Y, Cescutti P, Impallomeni G, Rizzo R. Exopolysaccharides produced by *Inquilinus limosus*, a new pathogen of cystic fibrosis patients: novel structures with usual components. *Carbohydr Res* 2007; **342**: 2404–2415.
262. Lau SK, Ho PL, Li MW *et al.* Cloning and characterization of a chromosomal class C beta-lactamase and its regulatory gene in *Laribacter hongkongensis*. *Antimicrob Agents Chemother* 2005; **49**: 1957–1964.
263. Woo PC, Ma SS, Teng JL *et al.* Construction of an inducible expression shuttle vector for *Laribacter hongkongensis*, a novel bacterium associated with gastroenteritis. *FEMS Microbiol Lett* 2005; **252**: 57–65.
264. Woo PC, Ma SS, Teng JL, Li MW, Lau SK, Yuen KY. Plasmid profile and construction of a small shuttle vector in *Laribacter hongkongensis*. *Biotechnol Lett* 2007; **29**: 1575–1582.
265. Woo PC, Teng JL, Ma SS, Lau SK, Yuen KY. Characterization of a novel cryptic plasmid, pHLHK26, in *Laribacter hongkongensis*. *New Microbiol* 2007; **30**: 139–147.
266. Han XY, Hong T, Falsen E. *Neisseria bacilliformis* sp. nov. isolated from human infections. *J Clin Microbiol* 2006; **44**: 474–479.
267. Daneshvar MI, Hollis DG, Weyant RS *et al.* *Paracoccus yeeii* sp. nov. (formerly CDC group EO-2), a novel bacterial species associated with human infection. *J Clin Microbiol* 2003; **41**: 1289–1294.
268. Dabboussi F, Hamze M, Singer E, Geoffroy V, Meyer JM, Izard D. *Pseudomonas mosselii* sp. nov., a novel species isolated from clinical specimens. *Int J Syst Evol Microbiol* 2002; **52**: 363–376.
269. Meyer JM, Geoffroy VA, Baida N *et al.* Siderophore typing, a powerful tool for the identification of fluorescent and nonfluorescent pseudomonads. *Appl Environ Microbiol* 2002; **68**: 2745–2753.
270. Clark LL, Dajcs JJ, McLean CH, Bartell JG, Stroman DW. *Pseudomonas otitidis* sp. nov., isolated from patients with otic infections. *Int J Syst Evol Microbiol* 2006; **56**: 709–714.
271. Chen WM, Laevens S, Lee TM *et al.* *Ralstonia taiwanensis* sp. nov., isolated from root nodules of *Mimosa* species and sputum of a cystic fibrosis patient. *Int J Syst Evol Microbiol* 2001; **51**: 1729–1735.
272. Kampfer P, Avesani V, Janssens M, Charlier J, De Baere T, Vaneechoutte M. Description of *Wautersia falsenii* gen. nov., sp. nov., to accommodate clinical isolates phenotypically resembling members of the genera *Chryseobacterium* and *Empedobacter*. *Int J Syst Evol Microbiol* 2006; **56**: 2323–2329.
273. Song Y, Liu C, Finegold SM. *Peptoniphilus gorbachii* sp. nov., *Peptoniphilus olsenii* sp. nov., and *Anaerococcus murchonii* sp. nov. isolated from clinical specimens of human origin. *J Clin Microbiol* 2007; **45**: 1746–1752.
274. Downes J, Wade WG. *Peptostreptococcus stomatis* sp. nov., isolated from the human oral cavity. *Int J Syst Evol Microbiol* 2006; **56**: 751–754.
275. Kononen E, Bryk A, Niemi P, Kanervo-Nordstrom A. Antimicrobial susceptibilities of *Peptostreptococcus anaerobius* and the newly described *Peptostreptococcus stomatis* isolated from various human sources. *Antimicrob Agents Chemother* 2007; **51**: 2205–2207.
276. Huys G, Vancanneyt M, D'Haene K, Falsen E, Wauters G, Vandamme P. *Alloscardovia omnicoles* gen. nov., sp. nov., from human clinical samples. *Int J Syst Evol Microbiol* 2007; **57**: 1442–1446.

277. Schwartz A, Hold GL, Duncan SH *et al.* *Anaerostipes caccae* gen. nov., sp. nov., a new saccharolytic, acetate-utilising, butyrate-producing bacterium from human faeces. *Syst Appl Microbiol* 2002; **25**: 46–51.
278. Duncan SH, Louis P, Flint HJ. Lactate-utilizing bacteria, isolated from human feces, that produce butyrate as a major fermentation product. *Appl Environ Microbiol* 2004; **70**: 5810–5817.
279. Song Y, Liu C, Molitoris DR *et al.* *Clostridium bolteae* sp. nov., isolated from human sources. *Syst Appl Microbiol* 2003; **26**: 84–89.
280. Ballard SA, Grabsch EA, Johnson PD, Grayson ML. Comparison of three PCR primer sets for identification of *vanB* gene carriage in feces and correlation with carriage of vancomycin-resistant enterococci: interference by *vanB*-containing anaerobic bacilli. *Antimicrob Agents Chemother* 2005; **49**: 77–81.
281. Finegold SM, Song Y, Liu C *et al.* *Clostridium clostridioforme*: a mixture of three clinically important species. *Eur J Clin Microbiol Infect Dis* 2005; **24**: 319–324.
282. Kitahara M, Takamine F, Imamura T, Benno Y. *Clostridium hiranonis* sp. nov., a human intestinal bacterium with bile acid 7 $\alpha$ -dehydroxylating activity. *Int J Syst Evol Microbiol* 2001; **51**: 39–44.
283. Kitahara M, Sakamoto M, Benno Y. PCR detection method of *Clostridium scindens* and *C. hiranonis* in human fecal samples. *Microbiol Immunol* 2001; **45**: 263–266.
284. Korenek NL, Andrews FM, Maddux JM, Sanders WL, Faulk DL. Determination of total protein concentration and viscosity of synovial fluid from the tibiotarsal joints of horses. *Am J Vet Res* 1992; **53**: 781–784.
285. Roos S, Engstrand L, Jonsson H. *Lactobacillus gastricus* sp. nov., *Lactobacillus antri* sp. nov., *Lactobacillus kalixensis* sp. nov. and *Lactobacillus ultunensis* sp. nov., isolated from human stomach mucosa. *Int J Syst Evol Microbiol* 2005; **55**: 77–82.
286. De Angelis M, Siragusa S, Berloco M *et al.* Selection of potential probiotic lactobacilli from pig feces to be used as additives in pelleted feeding. *Res Microbiol* 2006; **157**: 792–801.
287. Duncan SH, Hold GL, Barcenilla A, Stewart CS, Flint HJ. *Roseburia intestinalis* sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. *Int J Syst Evol Microbiol* 2002; **52**: 1615–1620.
288. Downes J, Munson MA, Radford DR, Spratt DA, Wade WG. *Shuttleworthia satelles* gen. nov., sp. nov., isolated from the human oral cavity. *Int J Syst Evol Microbiol* 2002; **52**: 1469–1475.
289. Hall V, Collins MD, Lawson PA *et al.* Characterization of some actinomyces-like isolates from human clinical sources: description of *Varibaculum cambriensis* gen nov, sp nov. *J Clin Microbiol* 2003; **41**: 640–644.
290. Jumas-Bilak E, Carlier JP, Jean-Pierre H *et al.* *Veillonella montpellierensis* sp. nov., a novel, anaerobic, Gram-negative coccus isolated from human clinical samples. *Int J Syst Evol Microbiol* 2004; **54**: 1311–1316.
291. Ravery C, Etienne A, Foucault C, Berger P, Brouqui P. *Veillonella montpellierensis* endocarditis. *Emerg Infect Dis* 2005; **11**: 1112–1114.
292. Song Y, Kononen E, Rautio M *et al.* *Alistipes onderdonkii* sp. nov. and *Alistipes shahii* sp. nov., of human origin. *Int J Syst Evol Microbiol* 2006; **56**: 1985–1990.
293. Bakir MA, Kitahara M, Sakamoto M, Matsumoto M, Benno Y. *Bacteroides intestinalis* sp. nov., isolated from human faeces. *Int J Syst Evol Microbiol* 2006; **56**: 151–154.
294. Kitahara M, Sakamoto M, Ike M, Sakata S, Benno Y. *Bacteroides plebeius* sp. nov. and *Bacteroides coprocola* sp. nov., isolated from human faeces. *Int J Syst Evol Microbiol* 2005; **55**: 2143–2147.
295. Finegold SM, Vaisanen ML, Molitoris DR *et al.* *Cetobacterium somerae* sp. nov. from human feces and emended description of the genus *Cetobacterium*. *Syst Appl Microbiol* 2003; **26**: 177–181.
296. Langendijk PS, Kulik EM, Sandmeier H, Meyer J, van der Hoeven JS. Isolation of *Desulfomicrobium orale* sp. nov. and *Desulfovibrio* strain NY682, oral sulfate-reducing bacteria involved in human periodontal disease. *Int J Syst Evol Microbiol* 2001; **51**: 1035–1044.
297. Downes J, Munson M, Wade WG. *Dialister invisus* sp. nov., isolated from the human oral cavity. *Int J Syst Evol Microbiol* 2003; **53**: 1937–1940.
298. Rocas IN, Siqueira JF Jr. Detection of novel oral species and phylotypes in symptomatic endodontic infections including abscesses. *FEMS Microbiol Lett* 2005; **250**: 279–285.
299. Rocas IN, Baumgartner JC, Xia T, Siqueira JF Jr. Prevalence of selected bacterial named species and uncultivated phylotypes in endodontic abscesses from two geographic locations. *J Endod* 2006; **32**: 1135–1138.
300. Jumas-Bilak E, Jean-Pierre H, Carlier JP *et al.* *Dialister micraerophilus* sp. nov. and *Dialister propionificiens* sp. nov., isolated from human clinical samples. *Int J Syst Evol Microbiol* 2005; **55**: 2471–2478.
301. Morio F, Jean-Pierre H, Dubreuil L *et al.* Antimicrobial susceptibilities and clinical sources of *Dialister* species. *Antimicrob Agents Chemother* 2007; **51**: 4498–4501.
302. Lawson PA, Falsen E, Inghan E, Weyant RS, Collins MD. *Dysgonomonas mossii* sp. nov., from human sources. *Syst Appl Microbiol* 2002; **25**: 194–197.
303. Matsumoto T, Kawakami Y, Oana K *et al.* First isolation of *Dysgonomonas mossii* from intestinal juice of a patient with pancreatic cancer. *Arch Med Res* 2006; **37**: 914–916.
304. Shukla SK, Meier PR, Mitchell PD, Frank DN, Reed KD. *Leptotrichia amnionii* sp. nov., a novel bacterium isolated from the amniotic fluid of a woman after intrauterine fetal demise. *J Clin Microbiol* 2002; **40**: 3346–3349.
305. Goto M, Hitomi S, Ishii T. Bacterial arthritis caused by *Leptotrichia amnionii*. *J Clin Microbiol* 2007; **45**: 2082–2083.
306. Boennelycke M, Christensen JJ, Arpi M, Krause S. *Leptotrichia amnionii* found in septic abortion in Denmark. *Scand J Infect Dis* 2007; **39**: 382–383.
307. Thilesen CM, Nicolaidis M, Lokebo JE, Falsen E, Jorde AT, Muller F. *Leptotrichia amnionii*, an emerging pathogen of the female urogenital tract. *J Clin Microbiol* 2007; **45**: 2344–2347.
308. Song Y, Liu C, Lee J, Bolanos M, Vaisanen ML, Finegold SM. '*Bacteroides goldsteinii* sp. nov.' isolated from clinical specimens of human intestinal origin. *J Clin Microbiol* 2005; **43**: 4522–4527.
309. Sakamoto M, Benno Y. Reclassification of *Bacteroides distasonis*, *Bacteroides goldsteinii* and *Bacteroides merdae* as *Parabacteroides distasonis* gen. nov., comb. nov., *Parabacteroides goldsteinii* comb. nov. and *Parabacteroides merdae* comb. nov. *Int J Syst Evol Microbiol* 2006; **56**: 1599–1605.

310. Summanen PH, Durmaz B, Vaisanen ML *et al.* *Porphyromonas somerae* sp. nov., a pathogen isolated from humans and distinct from *Porphyromonas levii*. *J Clin Microbiol* 2005; **43**: 4455–4459.
311. Finegold SM, Vaisanen ML, Rautio M *et al.* *Porphyromonas uenonis* sp. nov., a pathogen for humans distinct from *P. asaccharolytica* and *P. endodontalis*. *J Clin Microbiol* 2004; **42**: 5298–5301.
312. Downes J, Sutcliffe I, Tanner AC, Wade WG. *Prevotella marshii* sp. nov. and *Prevotella baroniae* sp. nov., isolated from the human oral cavity. *Int J Syst Evol Microbiol* 2005; **55**: 1551–1555.
313. Downes J, Sutcliffe IC, Hofstad T, Wade WG. *Prevotella bergensis* sp. nov., isolated from human infections. *Int J Syst Evol Microbiol* 2006; **56**: 609–612.
314. Hayashi H, Shibata K, Sakamoto M, Tomita S, Benno Y. *Prevotella copri* sp. nov. and *Prevotella stercorea* sp. nov., isolated from human faeces. *Int J Syst Evol Microbiol* 2007; **57**: 941–946.
315. Sakamoto M, Huang Y, Umeda M, Ishikawa I, Benno Y. *Prevotella multififormis* sp. nov., isolated from human subgingival plaque. *Int J Syst Evol Microbiol* 2005; **55**: 815–819.
316. Sakamoto M, Umeda M, Ishikawa I, Benno Y. *Prevotella multisaccharivorax* sp. nov., isolated from human subgingival plaque. *Int J Syst Evol Microbiol* 2005; **55**: 1839–1843.
317. Collins MD, Hoyles L, Tornqvist E, von Essen R, Falsen E. Characterization of some strains from human clinical sources which resemble '*Leptotrichia sanguinegens*': description of *Sneathia sanguinegens* sp. nov., gen. nov. *Syst Appl Microbiol* 2001; **24**: 358–361.
318. De Martino SJ, Mahoudeau I, Brettes JP, Piemont Y, Monteil H, Jaulhac B. Peripartum bacteremias due to *Leptotrichia amnionii* and *Sneathia sanguinegens*, rare causes of fever during and after delivery. *J Clin Microbiol* 2004; **42**: 5940–5943.
319. Wyss C, Dewhirst FE, Gmur R *et al.* *Treponema parvum* sp. nov., a small, glucuronic or galacturonic acid-dependent oral spirochaete from lesions of human periodontitis and acute necrotizing ulcerative gingivitis. *Int J Syst Evol Microbiol* 2001; **51**: 955–962.
320. Blackwood KS, Turenne CY, Harmsen D, Kabani AM. Reassessment of sequence-based targets for identification of bacillus species. *J Clin Microbiol* 2004; **42**: 1626–1630.
321. Turenne CY, Tschetter L, Wolfe J, Kabani A. Necessity of quality-controlled 16S rRNA gene sequence databases: identifying nontuberculous *Mycobacterium* species. *J Clin Microbiol* 2001; **39**: 3637–3648.
322. Patel JB, Wallace RJ Jr, Brown-Elliott BA *et al.* Sequence-based identification of aerobic actinomycetes. *J Clin Microbiol* 2004; **42**: 2530–2540.